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Extracorporeal photopheresis (ECP) is an effective, low-risk 
immunomodulating therapy for leukemic cutaneous T cell lymphoma (L-CTCL) 
and graft versus host disease (GVHD), but whether the mechanism(s) of action 
in these two diseases is (are) identical or different is unclear.  To determine the 
effects of ECP in vivo, we studied regulatory T cells (T-regs), cytotoxic T 
lymphocytes (CTLs), and dendritic cells (DCs) by immunofluorescence flow 
cytometry in 18 L-CTCL and 11 GVHD patients before and after ECP at Day 2, 1 
month, 3 months, and 6 months.  In this study, ECP was effective in 12/18 L-
CTCL patients with a 66.7% overall response rate (ORR) and 6/11 GVHD 
patients with a 54.5% ORR.  Prior to ECP, the percentages of CD4+Foxp3+ T 
cells in 9 L-CTCL patients were either lower (L-CTCL-Low, n=2) or higher (L-
CTCL-High, n=7) than normal.  Five of the 7 GVHD patients had high 
percentages of CD4+Foxp3+ T cells (GVHD-High).  Six of 7 L-CTCL-High patients 
had >80% CD4+Foxp3+ T cells which were correlated with tumor cells, and were 
responders.  Both L-CTCL-High and GVHD-High patients had decreased 
percentages of CD4+Foxp3+ and CD4+Foxp3+CD25- T cells after 3 months of 
treatment. CD4+Foxp3+CD25+ T cells increased in GVHD-High patients but 
decreased in L-CTCL-High patients after 3 months of ECP.  In addition, numbers 
of CTLs were abnormal.  We confirmed that numbers of CTLs were low in L-
CTCL patients, but high in GVHD patients prior to ECP.  After ECP, CTLs 
increased after 1 month in 4/6 L-CTCL patients whereas CTLs decreased after 6 
vii  
months in 3/3 GVHD patients.  Myeloid (mDCs) and plasmacytoid DCs (pDCs) 
were also low at baseline in L-CTCL and GVHD patients confirming the DC 
defect.  After 6 months of ECP, numbers and percentages of mDCs and pDCs 
increased in L-CTCL and GVHD.  MDCs were favorably increased in 8/12 L-
CTCL responders whereas pDCs were favorably increased in GVHD patients.  
These data suggest that ECP is favorably modulating the DC subsets.  In L-
CTCL patients, the mDCs may orchestrate Th1 cell responses to overcome 
immune suppression and facilitate disease regression.  However, in GVHD 
patients, ECP is favorably down-regulating the immune system and may be 
facilitating immune tolerance to auto-or allo-antigens.  In both L-CTCL and GVHD 
patients, DCs are modulated, but the T cell responses orchestrated by the DCs 
are different, suggesting that ECP modulates depending on the immune milieu.          
_______________                            
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CHAPTER 1 
GENERAL BACKGROUND 
1.1 Elements of the Immune System 
The immune system is comprised of differentiated hematopoeitic cells that 
arise from bone marrow hematopoietic stem cells (HSC) (Figure 1.1).  HSCs 
differentiate into various types of cells such as erythroid cells, platelets, myeloid 
cells such as neutrophils, basophils, eosinophils, monocytes, mast cells, natural 
killer cells, dendritic cells, natural killer T cells, and thymus derived cells (T cells), 
and B cells depending on the environment and stimuli [1].  For example, the 
HSCs that migrate to the thymus can develop into T cells where thymic 
epithelium –HSC interaction leads to deletion of naive T-cells recognizing self-
antigens and promotes survival of other T-cells that will become part of the 
intrinsic host response to neo-antigens.  After development, immune cells 
orchestrate host protection by responding against foreign antigens.  For these 
reactions to occur normally, a proper maintenance of molecular and cellular 
balance is vital.  Once awry, normal immunity is disrupted and disease with 
increased susceptibility to infection arises.  
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Figure 1.1.  Simplified schematic of immune cell development. 
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1.2 Innate and Adaptive Immunity 
Host defenses against pathogens are organized into two categories:  1) 
Innate and 2) Adaptive Immunity (Figure 1.2). Innate immunity is the fast-acting, 
front-line defense against all pathogens and is non-specific.  Adaptive immunity 
is activated by innate immunity and is a slow, antigen-specific response that can 
lead to formation of memory against foreign antigen.   
Innate immunity comprises of surface tissues such as the skin and 
intestinal tract, molecules such as Toll-like receptors (TLRs), and cells including 
neutrophils, macrophages, eosinophils, and dendritic cells.  The first line of 
defense in innate immunity includes the surface tissues which provide an 
inpenetrable barrier to the environment.  The skin, intestinal tract, respiratory 
tract, and reproductive tract epithelia interact with the external environment and 
continuously encounter bacteria, fungi, viruses, and pathogenic parasites.  As a 
result, these epithelia produce a diverse aramentium of antimicrobial proteins 
that can kill or inhibit microbial growth to manage the substantial microbial 
exposure. In addition, these surface tissues are challenged with defending a 
large surface area against pathogens while maintaining homeostasis of 
communities of commensal microorganisms.  To cope with microbial challenges, 
epithelial antimicrobial proteins (AMP) are produced and protect mammalian 
body surfaces.  AMPs are natural antibiotics that function to kill or inactivate 
microorganisms [2].  Defensins, cathelicidins, lysozyme, C-type lections (i.e. 
regenerating islet derived protein (REG) family, ribonucleases (RNAses, 
angiogenin 4 (ANG4), and S100 proteins (calprotectin, and psoriasin (S100A7) 
4  
are all distinct AMP protein families found in the skin and gut [2,3].  The physical 
surface tissues coupled with AMPs produced by epithelial cells provide a barrier 
to prevent pathogenic invasion.  When pathogens evade anti-pathogenic 
defense, protection is activated at the molecular and cellular level.  Phagocytic 
cells work quickly to contain the spread of invaders by sensing microbial 
components through Toll-like receptors (TLRs) as well as cellular pinocytosis and 
phagocytosis [4].  Neutrophils, macrophages, eosinophils, and dendritic cells 
(DCs) are types of phagocytic cells that can detect pathogens.  In addition to 
their phagocytic capability, dendritic cells also express TLRs which can bind 
bacterial components such as Flaggellin or LPS found on gram-postive bacteria 
and gram-negative bacteria.  This elicits an intracellular signaling casade that 
enhances cytokine secretion, upregulation of MHC and co-stimulatory molecules, 
and presentation of antigens.       
Not only do DCs play a role in innate immunity, but they also have a role 
in adaptive immunity.  They “bridge” innate and adaptive immunity by activating B 
and T cells through antigen presentation on their cell surfaces [5].  When B cells 
are triggered by DCs, a humoral response containing secretion of antigen 
specific antibodies occurs.  At the same time, DCs activate CD4+ helper and 
CD8+ T cells that elicit T cell responses specific to the antigen [6].  Depending on 
the type of antigen, different CD4+ T helper responses such as Th1, Th2, Th17, 
and T-reg can occur.  Corresponding Th cells also secrete cytokines that 
promote cell interactions with other cells which are recruited to the infected site.  
For example, the Th1 response is mediated by CD4+ helper T cells and CD8+ T 
5  
cells that secrete IFN-γ, IL-2, and IL-12 to fight against viruses.  The CD4+ helper 
cells “help” to elicit a cytotoxic attack against the virus, mainly through CD8+ 
cytotoxic T cells [7,8] .       
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Figure 1.2.  Diagram of cells involved in innate and adaptive 
immunity. 
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1.3 Dendritic Cells 
The architecture of the immune system includes a wide variety of cells that 
help to maintain homeostasis.  The balance between tolerance and immunity is 
tightly controlled by professional antigen presenting cells (APCs).  Professional 
APCs have antigen-uptake machinery and MHC class II-peptide complexes on 
the cell surface and can elicit T or B cell responses.  Dendritic cells (DC) are a 
type of professional APCs derived from hematopoietic precursors and have the 
capability to induce antigen-specific T or B cell responses.  First discovered in 
the spleen about 40 years ago by Ralph Steinmen, DCs delineate from the 
common myeloid progenitors, develop through the lymphoid pathway, and 
differentiate from monocytes [9].  They exist in all lymphoid, non-lymphoid 
tissues, and circulate in blood.  Their ubiquitious presence allows them to sample 
the environment through pattern recognition receptors (PPRs) such as TLRs or 
phagocytosis.  Through phagocytosis, DCs process antigens for cell surface 
presentation to alert the other defense cells.  Antigen presentation induces 
upregulation of co-stimulatory molecules such as B7 family molecules (e.g. 
CD80, CD86) and MHC molecules which allow interaction with multiple T cells 
and B cells in the periphery or in the lymph nodes [10] .   
The interactions between  DC MHC chains and co-stimulatory molecules 
with the T cell or B cell receptors initiates naïve T and B cell intracellular 
signaling that induces a primary immune response that result in extracellular 
cytokine secretion, extracellular and/or intracellular changes, and cellular 
differentiation (Figure 1.3).  Upregulation of stimulatory and MHC molecules on 
8  
DCs mark their transition from immature DCs to mature DCs status.  Naïve T 
cells become differentiated and acquire specificity in their response against the 
foreign antigen.  Naïve B cells also become differentiated into plasma cells that 
produce and secrete antibodies targeted against the foreign antigen [11].   
Although the DC family is heterogenous, it consists of different subsets 
that each have specific functional characteristics.  Two subsets that have been 
characterized in humans are myeloid DCs (mDC) and plasmacytoid DCs (pDC).  
The two subsets are distinguished by distinct expression of cell surface 
molecules and PPRs which determine their specialized functions.  Myeloid DC 
(mDC) are CD11c+ cells expressing myeloid markers (e.g.  CD13, CD33, and 
CD11b).  There are three subtypes of mDCs which can be identified by the 
expression of CD11c in combination with unique surface molecules CD1c 
(BDCA1), CD141 (BDCA3), and CD16 [12].  Immature mDCs reside in peripheral 
tissues and migrate to lymph nodes after their maturation during infection or 
inflammation to activate T cells and secrete IL-12 [13,14]. Plasmacytoid DCs 
(pDC) produce large amounts of type 1 IFNs in response to bacterial or viral 
stimuli.   The high levels of type 1 IFNs enable communication between pDCs 
and mDCs, natural killer cells, and B cells.  These IFNs stimulate mDCs to 
enhance T-cell activation and activate natural killer and B cells.  During infection, 
single-stranded viral RNA or unmethylated CpG DNA motifs are recognized by 
TLR-7 and TLR-8, respectively, which are located in intracellular endosomes and 
lysosomes.  In steady-state conditions, pDCs circulate through the body after 
entering the bloodstream and migrate to secondary lymphoid organs through 
9  
high endothelial venules.  After inflammation, pDCs accumulate at the infectious 
site to take up antigens and then migrate to the lymph nodes to present the 
encountered antigen [15,16].   
PDCs are CD11c- cells without myeloid markers but with plasmacytoid 
morphology, a well-developed Golgi apparatus, and rough endoplasmic 
reticulum.  Although mDCs possess myeloid markers and pDCs do not, their 
developmental pathways remain unclear but cannot be categorized by the 
conventional myeloid or lymphoid pathway [17].  Therefore, it is challenging to 
identify mDCs and pDCs by lineage markers.  The current method of identifying 
mDCs and pDCs by extraceullar immunofluorescence flow cytometry is by 
excluding lineage markers for other cells (CD3, CD14, CD16, CD19, CD20, 
CD56), while detecting  expression of HLA-DR (MHC II), and CD11c or CD123 
(IL-3Rα ).  Thus, mDCs are identified in this dissertation as Lineage-, HLA-
DR+CD11c+ and pDCs are identified as Lineage-HLA-DR+CD123+.    
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Figure 1.3.  Adaptive Immunity:  DC and T cell interactions. Reprinted 
by permission from Macmillan Publishers Ltd: Nature Reviews 
Immunology, [18], copyright (2004). 
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1.4 T cells 
T cells delineate from HSCs and mature in the thymus.  Expression of self 
antigens in the thymic epithelium provides proper T cell education and 
development.  T cells interact with DCs or thymic epithelial cells for instruction of 
proper function.  Through a process termed negative selection, naïve T cells are 
tested against protein chains found on conjugate cells called major 
histocompatibility complexes (MHC).  MHC I presents the self peptide and is 
found on all cells and distinguishes all cells as “self”.  It is vital that T cells do not 
strongly react with MHC I + self peptide, otherwise autoimmunity would occur.  
Thus, during developmental negative selection, T cells that do react to “self” 
antigens are deleted whereas T cells that do not react with “self” are retained and 
further differentiate into functionally distinct T-cell subgroups which react to and 
produce different cytokine profiles [19].   
Although there are natural killer T cells and γδ T cells, two major types of 
αβ T cells include the CD4+ T helper (Th) and CD8+ cytotoxic T lymphocytes.  
CD4 and CD8 are surface molecules that are part of the T-cell receptor 
complexes which facilitate binding to MHC II or I on CD4+ or CD8+ cells, 
respectively [20,21] (Figure 1.3).  
Multiple types of CD4+ T helper cells exist.  Naïve T cells can differentiate 
into distinct CD4+ lineages such as Th1, Th2, Th17, T-reg, and Tfh based on 
transcription factors and cytokines (Figure 1.4A).  The differentiation of CD4+ Th 
cells was previously viewed as inconvertible linear developmental pathways; 
however more recently, current studies have challenged this classical view 
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suggesting that differentiated Th cells can change into other types of Th cells 
(Figure 1.4B) [22]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13  
 
Figure 1.4.  CD4+ Th cell differentiation. A)  Classical view of Th differentiation:  
Differentiation pathways are not convertible.  B)  Modern view of Th 
differentiation:  Flexibility and plasticity of Th differentiation where differentiated 
Th cells can adopt new phenotypes.  From [22]. Reprinted with permission from 
AAAS.       
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1.5 DC subsets and T cell immunity 
Differences in mDC and pDC cellular markers underlie differences in 
cellular function.  Although both mDCs and pDCs have functional plasticity to 
elicit an appropriate immune response through T cells, it is their reaction to 
specific stimuli and environment that promotes two major divergent responses T 
helper 1 (Th1) and T helper 2 (Th2) immune responses, which are associated 
with inflammation and allergy/antibody response, respectively.   Th responses 
produce specific cytokines that aid in the orchestration of appropriate defenses.  
The Th1 response produces IL-2, IFN-γ, IL-12, and tumor necrosis factor (TNF) 
cytokines and the Th 2 response produces IL-4, IL-5, IL-10, and transforming 
growth factor (TGF-β) cytokines.  At the cellular level, Th1 responses are mainly 
associated with cytotoxic T lymphocytes whereas Th2 responses are associated 
with induction of eosinophils and B cells.  Since DCs conduct T cell responses, 
pDCs can elicit a Th2 response whereas mDCs favor a Th1 response [23].  
When activated by CD40 ligand (CD40L), monocyte-derived mDCs induce Th1 
development with IFN-γ and IL-12 production.  However, when pDCs are 
activated by CD40L, they produce lower amounts of IL-12 and induce Th2 
development.  [24,25] (Figure 1.5).       
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Figure 1.5.  Human DC subsets induce different CD4+ T cell responses 
based on environment and stimuli. A) Monocytes in innate immunity respond 
to bacterial components through Toll-like receptor (TLRs) and secrete pro-
inflammatory cytokines, TNF-α and IL-6.  Subsequently, monocyte-derived DCs 
induced by GM-CSF and IL-4 can induce a Th1 response against microbes.  In 
contrast, moncyte-derived DCs stimulated by mast cells and PGE2 can induce a 
Th2 response.  B) In response to bacterial and viral components through TLRs, 
myeloid DCs (mDCs) secrete IL-12 and induce a Th1 response.  However, when 
stimulated with Thymic stromal lymphoprotein (TSLP), mDCs can induce a Th2 
response by OX40-OX40L interaction.  C)  Plasmacytoid DCs (pDCs) produce 
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IFN-α in response to viral components sensed through TLR7 and TLR9.  pDCs 
stimulated with viruses induce cytotoxic regulatory T cells that secrete IL-10, 
whereas pDCs stimulated with IL-3 induce  a Th2 response through OX40-
OX40L ligation.  ICOS ligand on pDCs induces IL-10 producing T cells, which are 
important in immunoregulation.  From [8]. Reprinted with permission from 
Japanese Society of Allergology-Allergology International.               
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1.6 Regulatory T cells 
Regulatory T cells (T-regs) are a subset of CD4+ T helper cells that have 
immunosuppressive and immunoregulatory capabilities and are anergic or lack 
proliferative response upon T cell receptor activation.  Discovered in 1969 in 
mice thymectomy experiments, the thymus-derived cell subset termed 
“suppressor cells” were found to be important in self-tolerance and preventing 
autoimmunity [26-28].  In 1995, suppressor cells were rediscovered and termed 
regulatory T cells.  These suppressive T-regs were phenotypically characterized 
as CD4+ T cells expressing CD25 (IL-2Rα) in mice [26,29].  However, there were 
caveats to the use of CD25 as a unique marker for T-regs.  CD25 is also 
expressed on activated T cells and its expression is very dynamic.  The 
CD4+CD25+ T cell population seems to be heterogeneous with a portion of cells 
exerting suppressive function, such as CD4+CD25high T cells.  However, in mice, 
CD4+CD25- T cells also had suppressive function.  Subsequently, in 2000 and 
2001, suppressive Foxp3 and CD25high expressing CD4+ T cells were found to be 
associated with suppressive T-regs in humans [30,31].  Although the spectrum of 
regulatory T cells includes multiple different T cell subsets, this dissertation will 
focus on Foxp3+ T –regs.   
Foxp3 is a forkhead transcription factor vital to the development and 
function of human regulatory T cells (T-regs).  Foxp3 is vital because when 
mutated, there was a lack of suppressive T-regs and resulted in fatal multiorgan 
autoimmune disease in mice (Scurfy) and humans (Polyendocrinopathy, 
Enteropthy, X linked syndrome (IPEX)) [32-34].  When Foxp3 was ectopically 
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expressed in CD4+ non-T-regs cells, suppressor function was conferred in vitro 
and in vivo.  Thus, Foxp3 may be an exclusive marker for CD4+ regulatory T 
cells.    
T-regs comprise of 5-10% of total peripheral blood mononuclear cells.  
They functionally regulate a wide variety of immune cells such as CD4+, CD8+, 
natural killer, natural killer T cells, B cells, and antigen-presenting cells both in 
vitro and in vivo [35].  The unique capabilities of T-regs to regulate immune 
reactions allow them to prevent immune diseases such as autoimmunity and 
allergy.  They also play a role in allograft tolerance as well as fetal-maternal 
tolerance during pregnancy.  In addition to their normal regulatory function, T-
regs can also impede anti-tumor responses to favor tumor progression.  Many 
failures of cancer vaccines have been attributed to T-regs.  However, T-regs also 
have potential use in clinical applications for dysregulated immunity.  Cellular 
therapy involving in vivo expansion of T-reg in patients with autoimmune disease 
would be ideal for treatment.  Likewise, strategies to remove T-regs may be 
helpful in augmenting a cytotoxic response to tumor antigens.      
1.7 Cytotoxic T lymphocytes 
Cytotoxic T lymphocytes (CTL) confer immunity against viruses and 
cancer.  Discovered in 1968, cytotoxic T lymphocytes’ specific cell mediated 
destruction function allows for eradication of unwanted cells while leaving 
bystander cells intact [36].  Because of their ability to specifically target antigens 
on cells, they have been of immunologic interest for anti-tumor immunity and role 
in vaccination responses to prevent infectious diseases.     
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Their cytotoxic function to specifically kill target cells relies on the 
molecules present on the CTL cell surface and within the cytolytic synapse 
formed with target cells.  CTLs express the CD8+ molecule with the T cell 
receptor. In the cytolytic synapse, the molecules form a bull’s eye with the TCR in 
the center.  The TCR ligates with the MHC I on the target cells.  At the CTL/target 
cell interface, cytolytic granules (perforin and granzymes) are released to lyse 
and kill the target cell [37].  Perforin, granules that perforate the cellular 
membrane, are first released and then granzymes enter the cell through the 
perforated membrane.  To date, this is the well accepted mechanism of cytotoxic 
action [38].  However, much of the protein machinery used has yet to be 
identified and the cytotoxic process has yet to be completely elucidated.  
Cytotoxic T lymphocytes can be idenfied by expression of cell surface 
CD8, CD69 marker and IFN-γ cytokine secretion.  CD69, a transmembrane C-
type lectin protein receptor involved in lymphocyte proliferation and transmission 
of external signals to the inside, is expressed when CD8+ T lymphocytes are 
activated through docking of CD8 + TCR on target cell MHC class I + peptide 
[39,40].  CD69 activation along with cytotoxic function produces interferon-
gamma (IFN-γ).  IFN-γ is a type II IFN cytokine that signals through the JAK-
STAT pathway and helps to promote an adaptive immune response against 
bacteria/viruses and tumors.  It is secreted in CD8+ T cells that have cytotoxic 
function [41,42], [43].  Thus, a current method of identifying CTL by flow 
cytometry is by intracellular expression of IFN-γ along with CD3, CD8, and CD69 
markers [44-46].   
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1.8 Cutaneous T cell Lymphoma (CTCL): Immunopathogenesis  
Cutaneous T-cell lymphomas (CTCL) are a heterogenous group of non-
Hodgkin’s peripheral T cell lymphomas that mainly impair skin. Mycosis 
Fungoides (MF) and Sézary Sydrome (SS) are the most common CTCLs.  They 
are characterized by clonal skin-homing memory CD4+ T cells and impaired 
immunity.  Together they comprise of about 70% of CTCL cases and affect 6.4 
per million persons.  Approximately 1,500 new cases of MF/SS are reported 
every year and about 16,000-20,000 persons are found alive with MF/SS in the 
United States [47].  For the most part, CTCLs are incurable and thought to arise 
from uncontrolled proliferation and accumulation of atypical mature helper, 
memory clonal T lymphocytes [48-50].  Some patients with advanced MF and 
those with Sezary Syndrome defined as erythroderma and > 1000/μL atypical 
circulating malignant T cells in blood are called leukemic L-CTCL (L-CTCL)      
1.9 Sézary Syndrome (SS): History and Clinical Presentation 
First described by Albert Sézary in 1938, SS is a leukemia comprised of 
circulating cells with cerebriform nuclei, skin erythroderma, pruritus, and 
adenopathy.  Patients with SS have the worst prognosis amongst all CTCL 
patients with a median overall survival (OS) of only 3 years [51].  Amongst the 
SS patients, we found that ≥10,000 Sézary cells/L is associated with the poorest 
prognosis with a median OS of 2.4 years whereas other patients have a median 
OS of >5 years [52].  SS patients typically expire from secondary and/or 
nosocomial infections, most often from Staphylococcus aureus (Staph) sepsis 
due to an impaired immune system, breaks in the integument and use of 
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catheters.  SS patients have a high rate of Staph colonization.  Staphylococci 
secrete erythro-toxins that cause erythroderma of skin when present in 
fentamolar concentrations.  Exfoliative erythroderma is defined as pink or red 
skin over 80% of the body.  It may be accompanied by pruritus, scaling, 
infiltration, keratoderma and ectropism.  Due to the bright red color exhibited 
diffusely on the skin, SS has been nicknamed as the “red man syndrome” 
although erythroderma may also be seen with atopic dermatitis, psoriasis, PRP, 
and other skin diseases.  The cause of SS is unknown but can be mimicked as 
exfoliative dermatitis, making diagnosis difficult.   
SS was first thought to arise from MF and may do so in a subset of 
patients.  Recent studies suggest that MF and SS can be separated based on 
the presence of distinct T cell subsets.  MF cells are effector memory T cells 
whereas SS cells are central memory T cells [53].  Found both in the blood and 
skin, Sèzary cells are also currently recognized as CD4+ T cells lacking CD26 or 
CD7 expression [54,55].  Clonal tumor T cell populations are sometimes 
identifiable by TCR Vβ clonality studies although some patients have a high 
percentages of cells that are not detected by the currently available antibodies 
[55].   
1.10 CTCL skin and clinical pathology 
Mycosis fungoides most often presents with patches or plaques while 
tumors appear later in the course.  All three types of skin lesions contain skin 
homing epidermotropic CD4+ helper memory T cells.  SS, the leukemic variant, 
presents with exfoliative erythroderma (red scaly skin over > 80% of the body) 
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and >1000 circulating atypical CD4+CD26- T cells, with common bone marrow 
and lymph node involvement [49,50].  SS can arise de novo or evolve from pre-
existing MF [56].  CD8+ and CD4, CD8 double negative variants have also been 
described.  Although SS cells are slow growing malignant cells and are 
characteristically anergic, accumulation of these tumor cells in the skin disrupts 
normal immune barrier function.  In addition to skin involvement, the presence of 
tumor cells in blood, bone marrow, and lymph nodes is associated with worse 
outcomes [57] 
MF typically begins as patches or plaques similar in clinical appearance to 
eczema or psoriasis.  Because early MF is a chronic eczematous dermatitis, a 
definitive biopsy is often delayed.  Breaks in the skin barrier found as a feature of 
eczema which may be due to a negative mutation in Filaggrin can induce release 
of cytokines, epidermal proliferation and attraction of inflammatory T cells.  In 
early MF, an infiltrate of atypical lymphocytes with hyperchromatic, convoluted, 
cerebrifom nuclei are found around vessels in the dermis.  Epidermatropism is a 
key feature required for the diagnosis of MF—either as single cells along the 
dermis-epidermal junction or as collections of cells known as Pautrier’s 
microabscesses composed as clusters of T cells surrounding Langerhan cells.  
However, in contrast, de novo SS patients’ biopsies contain perivascular rather 
than epidermotorpic atypical lymphocytic infiltrates and the diagnosis is often 
missed or delayed [58].   
1.11 CTCL tumor T cell abnormalities (Immunophenotype) 
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Abnormal T lymphocytes found in CTCL lesions are aberrant in 
development, cell migration, cell survival, cell proliferation, and apoptosis.  
Although malignant cells are memory CD4+CD45RO+ T helper cells in both MF 
and SS, recent studies classified MF as an outgrowth of effector memory T cells 
whereas SS are central memory T cells [53,59].  In addition to this distinction, 
cellular markers also differentiate MF and SS.  Compared to SS cells, MF cells 
are more localized to the skin.  In MF cell lines, the level of skin-homing 
chemokine receptor, CCR4, expression is much higher than in SS cell lines 
suggesting that MF cells are more localized to the epidermis [60].  Additionally, 
SS cells have a different phenotype from MF.  SS cells are currently identified as 
CD4+CD26- and sometimes CD4+CD7-  and expansion of a specific TCR Vβ 
clone.  CXCL13, a chemokine found to be high in SS cells, induces not only skin 
but lymph node homing properties when combined with CCR7 agonists 
expressed in the lymph nodes, CCL19 and CCL21 [61]. 
1.12 Impaired immunity in CTCL 
Normal immunity with T cell diversity allows protection from various 
antigens.  The variations of T cells are created by the T cell receptor (TCR) 
rearrangements at the genomic level and expression on the surface of T cells.  
Unique TCR are created by deletions in genomic DNA capable of recognizing 
foreign antigens presented on MHC.  In L-CTCL, single clones predominate and 
the normal T cell repertoire is lost.  These clones can be detected by flow 
cytometry and PCR amplification of TCRVβ or Vγ genes.   Decrease of T-cell 
receptor excision circles during early T cell development in association with loss 
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of T cell repertoire complexity through CDR3 spectratyping contribute to 
development of clones [59,62].  The diversity of T cell repertoire was recovered 
when patients were successful treated [63].   
Due to the loss of T cell variety in L-CTCL patients, CD8+ T cells are 
abnormally low and consequently hypothesized that the numbers of cytotoxic T 
lymphocytes are also low due to depressed cell-mediated cytotoxicity marked by 
Th2 dominance with eosinophilia and elevated serum IgE and IgA [64-66]. This 
imbalance also reduces the activity of natural killer cells.   
Since CD4+ T cells are directed by DC or antigen presenting cells through 
TCR:MHC II antigen presentation, it has been reported that DC are ‘helping 
hands’ in L-CTCL progression [67].  The two main DC subsets in humans, 
Lineage 1 -HLA-DR+CD11c+myeloid DCs and Lineage 1-HLA-
DR+CD123+plasmacytoid DCs, were found to be defective in numbers and 
function in SS patients [68].  The failure of DCs to elicit normal responses and 
prevent tumor cell outgrowth suggest an immunopathogenic role of DC.  
Stimulaton of malignant L-CTCL cells with immature dendritic cells loaded with 
apoptotic-T-cells in vitro exhibited a T-reg like phenotype [69].  Not only did this 
study provide evidence of DC eliciting L-CTCL outgrowth, but it also suggests 
that L-CTCL is an outgrowth of T-regs.  However, conflicting studies show a lack 
of Foxp3 expression and suppressive function in skin and blood of L-CTCL 
patients, suggesting that L-CTCL is not a malignancy of T-regs, but normal T-
regs may be a favorable prognostic factor [70-72].  Of interest, a recent study by 
Heid et al reported findings of a subgroup of L-CTCL patients with malignant cells 
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that were functionally suppressive and were CD4+Foxp3+CD25-T cells [73].  
Taken together, these studies reveal the controversy over whether L-CTCL 
malignant cells are T-regs or not.  Thus, the role of T-regs in L-CTCL remains 
unclear.   
1.13 SS and current treatments 
Since SS affects the skin as well as the blood, palliative topical treatment 
agents are used but are ineffective for anything except symptom control.  
Immunomodulatory and biological response modifiers that increase Th1 immunity 
such as IFN-alpha or oral retinoids, or fusion proteins are first line therapy 
combined with extracorporeal photopheresis (ECP).  Second line therapies 
include histone deacetylases (HDAC) inhibitors, and experimental monoclonal 
antibodies directed to tumor cells (Table 1).  Our recent studies have shown that 
Syndecan-4, a heparin sulfate proteoglycan, expressed on activated T cells can 
be depleted with dendritic cell-associated heparan sulfate proteoglycan-
dependent integrin ligand (DC-HIL) conjugated with saporin (a toxin) suggesting 
a novel opportunity to treat T cell mediated diseases [74].          
Effective treatment options to reduce tumor burden and regain normal T-
cell function are limited to ECP and biological response modifiers (BRM) while 
other available therapies are  immunosuppressive [75].  Treatment induced 
immunosuppression coupled with disease-related immunosuppression means 
that these patients frequently succumb to opportunistic infections especially 
Staph aureus.  Although a possible curative therapy for SS is non-ablative 
allogeneic human stem cell transplantation (HSCT), it is feasible for only a subset 
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of younger healthy patients and may cause mortality from infection, disease 
reoccurrence, and chronic graft-versus-host disease (cGVHD) [76].  Treatment of 
GVHD requires major immunosuppressive therapy which can lead to 
opportunistic infections.  Therapy with extracorporeal photopheresis (ECP) is 
effective with minimal toxicity and favorably modulates immunity.  Due to its 
beneficial immunomodulatory effects, the mechanism of ECP action in vivo is 
under investigation.   
1.14 Graft versus Host disease: Immunopathogenesis 
Graft versus host disease (GVHD) is an immunologic disorder that limits 
wide use of allogeneic stem cell/bone marrow transplant therapy.  The donor 
immune cells in the transplant recognize host cells as being foreign based on 
HLA mismatch.  The donor cells mount an immunological attack resulting in 
damage to organs including the skin, gut, liver, eyes, or lung.   
In 1966, Billingham established 3 criteria necessary for GVHD:  1) 
Transplanted graft has immunologically competent cells.  2)  The host/recipient is 
histoincompatible or has antigens that are lacking from the transplant so that the 
host appears foreign.  3)  The host/recipient is immunologically innocuous or 
immunocompromised [77].   Two types of GVHD are characterized by 
occurrence based on time after transplant.  Acute GVHD is defined as occurring 
within 100 days post-transplant and chronic GVHD is defined as disease that 
occurs after 100 days post-transplant.  In acute GVHD, a retrospective analysis 
revealed that 81% patients had skin involvement, 54% had gastrointestinal (GI) 
involvement, and 50% had liver involvement [78].   
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According to Ferrara et al, GVHD is considered as a three-step process:  
1) tissue damage to the recipient by pre-existing infections and/or 
radiation/chemotherapy pre-transplant conditioning regimen and antigen 
presenting cell activation; 2) T cell activation and clonal expansion of donor T 
cells; and 3) cellular and inflammatory factors [79].  Prior to the infusion of donor 
cells, the patient’s tissues have already been damaged by a host of factors such 
as underlying disease and its treatment, infection, and the condition regimen 
involving drugs and radiation.   This damage activates host antigen presenting 
cells (APCs) that are vital in activating donor T cells.  High intensity 
chemoradiotherapy also activates APCs.  Inflammatory cytokines such as TNF-
alpha and IL-1 are secreted from host tissues as a result of total body irradiation.  
Subsequently, they induce endothelial apoptosis leading to epithelial cell damage 
in the GI tract.  GI damage may amplify severity of GVHD if microbial products 
invade the systemic circulation.  These inflammatory and microbial products such 
as lipopolysaccharide (LPS) are mediators of an immune response or tolerance.  
They are immune ‘danger signals’ [80].  APCs activated by these danger signals 
can steer the immune response towards activation or tolerance [81].                            
At the molecular and cellular level, major histocompatibililty complex 
(MHC), CD4+ and CD8+ T cells, and cytokines are the main disease mediators.  
The MHC is vital in the recognition of foreign antigens that invade the immune 
system as it is unique to each individual.  MHC encodes heterogenous protein 
chains that present antigen to T cells through the T cell receptor and 
communicates in an autologous or matched setting.  The TCR: MHC interaction 
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directs the T cells activity by activating or inactivating it.  In the case of GVHD, 
graft T cells that fail to recognize the MHC proteins on host cells mount an 
immunologic attack against the host cells.  Since the host is seen as foreign due 
to MHC mismatch, the graft T cells attack the host cells.  However, if there is a 
match at the MHC loci, GVHD can also occur due to incompatibility of minor 
histocompatible antigens.  Since CD4+ and CD8+ T cells are matched by MHC II 
and MHC I, respectively, they elicit a T cell attack due to the lack of self 
recognition (Table 1.1).  T cells are previously educated in the thymus to 
recognize self and delete autoreactive cells in a process termed “negative 
selection” [82]. Thus, the MHC and minor histocompatible antigen mismatch 
attributes to the disrupted normal immunity leading to GVHD.   
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Table 1.1.  Comparison of L-CTCL and GVHD disease characteristics and 
treatment options.   
 
 
 
  
L-CTCL-Sézary 
 
GVHD 
Clinical Manifestations Skin-Erythroderma, pruritus Skin-Scleroderma 
Disease mediated cell type CD4+ T cells: CD4+CD26-  
Low CD8+ T cells 
CD4+ T cells 
CD8+  T cells 
Cytokines Th2 dominant:  IL-4, IL-5, 
Decreased IL-2 and IFN-γ  
Th1 dominant: IL-2, IL-12, 
TNF-α, IFN-γ   
Treatment strategy and 
options 
IMMUNOMODULATORY: 
Extracorporeal photopheresis 
plus interferon-γ,α,  
bexarotene, Denileukin 
Difitox, retinoids, steroids,  
Stem cell transplant - allo  
IMMUNOSUPRESSIVE:   
campath, chemotherapy, 
targeted antibodies, HDAC 
inhibitors.  
IMMUNOSUPPRESSIVE: 
Extracorporeal 
photopheresis, 
Glucocorticoids , 
cyclosporine, tacrolimus,  
rituximab 
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1.15. Extracorporeal Photopheresis (ECP):  History and Procedure 
Initially developed in 1987 for the treatment of patients with high numbers 
of circulating SS cells and with erythrodermic L-CTCL,  ECP is extremely well-
tolerated with minimal side effects, improves patients' quality of life, and 
increases overall survival [83].  ECP was first approved by the FDA in 1987 for 
the treatment of erythrodermic L-CTCL based on a multicenter clinical trial by 
Edelson et al.   Response rates between 54% and 66% have been reported in L-
CTCL patients with about 10% complete responders [84,85].  In the ECP 
procedure, 5x109 white blood cells (5-10% of PBMCs) are removed by 
leukopheresis, sensitized ex vivo with a plant-derived psoralen drug, 8- 
methoxypsoralen (8-MOP), and irradiated with 1.5 J/cm2 ultraviolet (UVA) light.  
The cells are re-infused back into the hosts’ circulation (Figure 1.6).  Not only is 
ECP used to treat SS, but it is also effectively used to treat diseases of an 
inflammatory/autoimmune etiology such as scleroderma, scleromyxedema, 
fibrosing nephrogenic dermatopathy, organ transplant rejection, and 
inflammatory bowel disease, etc [86-90].  How ECP can favorably treat a disease 
of malignant T-cells with a possible over-abundance of T-regs and a Th2 
phenotype as well as GVHD with a lack of T-regs and a Th1 phenotype is not yet 
understood. 
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Figure 1.6. Schematic view of ECP procedure.  Reprinted with 
permission from Therakos. 
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1.16. ECP:  Apoptosis  
SS tumor cells have aberrant apoptotic pathways including decreased 
Fas/Fas L and c-myc expression [91].  These defects in cell death or apoptosis 
are hypothesized to contribute to the accumulation and imbalance of tumor T 
cells within the blood and skin.     
Following ECP, the radiated tumor cells undergo apoptosis at 24 hours 
after treatment [92].  How apoptosis and cell cycle arrest occurs is in part 
attributed to the DNA damage caused by covalently crosslinking thymidine bases 
in lymphoma cells elicited by the 8-MOP and UVA light [93-96].   
Apoptosis is a programmed cell death process and apoptotic cells induced 
by ECP have effects on the patients’ immune system.  Apoptotic cells following 
ECP are sensed by the immune system by phagocytic dendritic cells.  These 
“professional antigen presenting” cells control immune responses by sampling 
the environment.  Following the uptake of apoptotic cells, DCs can promote an 
immunologically innocuous and/or tolerizing effect.  However, in some instances, 
apoptotic cells provide an attractive immunogenic antigen source to DCs for 
cross-priming cytotoxic T lymphocytes.  Since only a small portion of the total 
tumor lymphocytes are treated by ECP and prolonged clinical responses can be 
observed, ECP is hypothesized to induce beneficial immunomodulating effects in 
vivo.  What occurs after the apoptotic cells are re-infused into SS and GVHD 
patients and how it affects the patients' immune system in vivo are largely 
unknown and is the subject of this dissertation. 
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1.17 Immunomodulation by ECP: Vaccination Theory vs. Tolerance 
The classic hypothesis of how ECP works upon re-infusion of photo-
damaged PBMCs into the host’s circulation is the ‘vaccination’ theory [97].  Part 
of the ECP procedure circulates psoralen-treated white blood cells within a 
plastic chamber during UVA irradiation leading to photoactivation of 8-MOP.  
Upon photoactivation, 8-MOP intercalates into the DNA of tumor lymphocytes 
and induces apoptosis.  Monocytes, however, are suggested to differentiate into 
dendritic cells and become more receptive to the uptake and processing of 
apoptotic cells within the plastic chamber.  Studies prolonging interactions with 
DCs and apoptotic tumor cells by overnight incubation called “transimmunization” 
have shown to be therapeutically effective when reinfused into the patient the 
next day [98,99].  Transimmunization suggests that a therapeutically significant 
immunobiologic modifying response orchestrated by DCs is capable by ECP to 
specifically target tumors cells supports the vaccination theory of ECP 
mechanism of action after re-infusion.  As these apoptotic tumor lymphocytes are 
a source of tumor antigen, re-infusion of tumor-antigen loaded DCs is 
hypothesized to induce a vaccination response [67,98,100].  Mature dendritic 
cells facilitate in vivo CD8+ T-cell maturation into cytotoxic T cells that elicit a 
tumor specific attack on SS tumor cells while preserving non-pathogenic cells 
[67,98,101].  Thus, DC subsets may provide evidence of ECP response. The two 
DC subsets myeloid (mDC) and plasmacytoid DCs (pDC) in normal humans 
have been found to induce Th1 and Th2 responses, respectively [23].  In SS 
patients, DC subsets have been found to be depressed compared to healthy 
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controls [68].   Efforts to increase DCs would be logical for therapy and increase 
of a specific DC subset may be indicative of the in vivo T cell response.   
Since CD8+ T-cells are dramatically reduced in many patients with SS and 
low CD8 numbers are associated with poor prognosis and poor response to 
ECP, strategies to increase their numbers may be helpful in treating SS.   ECP 
treated patients with close to normal levels of CD8+ T cells are observed to 
respond better [102,103].  Modulation of the immune system by ECP appears to 
restore the production of Th1 cytokines and may allow monocytes to become 
effective tumor-antigen presenting cells to induce cytotoxic responses against 
tumor T cells [104-107] .  Additionally, these Th1 cytokines may promote 
“normal” immunity in SS patients required for cellular immunity, and defense 
against opportunistic infections [108].   
However, in GVHD patients, the vaccination theory is illogical.  Increase of 
CD8+ T cells and Th1 cytokines would exacerbate GVHD.  A previous report 
showed that in GVHD, treatment with ECP is associated with a shift from 
predominantly a Th1 (IL-2, INF-γ) to a Th2 (IL-4, IL-10) immune response [109], 
suggesting that ECP is down-regulating Th1 immunity.  Thus, it is proposed that 
ECP works by immunosuppression.  When apoptotic cells are endocytosed by 
DCs, DCs may elicit CD4+ regulatory T cells (T-regs). A recent study reported 
CD4+25high T cells, or T-regs increased in GVHD patients but decreased in L-
CTCL patients after six months of ECP [110].  These findings suggest that 
immunosuppression through T-regs occurs in GVHD patients but not in L-CTCL 
patients and favors the immunostimulatory or vaccination hypothesis in L-CTCL 
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patients.  In addition to GVHD, other Th1-mediated conditions such as 
transplantation and autoimmune disorders benefit with immunosuppression of 
inflammatory responses.  In these disorders, immunotolerant DCs are generated 
through the uptake of apoptotic cells and induce T-regs, cells that suppress 
immunity [111].   One previous study on the effect of ECP in the GVHD murine 
model reported that increased T-regs improved disease [112].  Other studies in 
transplantation show that T-regs are induced after ECP and prevent GVHD and 
suppress autoimmunity [113-115].  Thus, it is currently well accepted that T-regs 
suppress the pathogenic cells in Th1 mediated diseases, but what specific types 
of DCs or where the T-regs originate are unclear.  Further validation of the 
mechanism of ECP in L-CTCL and GVHD patients is needed and could provide 
information for better treatment. It is hypothesized that the mechanism of ECP 
action in GVHD is through immunotolerance and induction of regulatory T cells 
while immunostimulation and induction of cytotoxic T lymphocytes occur in L-
CTCL.    
 
1.18 Dissertation Objective and Hypothesis 
The overall objective of this investigation is to elucidate the immunological 
mechanisms of ECP and determine whether they are similar or different in L-
CTCL and GVHD patients.  Regulatory T lymphocytes, Cytotoxic CD8+ T 
lymphocytes, and Dendritic cell subsets from peripheral blood in L-CTCL versus 
GVHD patients will be examined.   Studies will be associated with clinical 
response to ECP and the mechanism will be compared between the two patient 
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populations.  To execute this objective, I utilized peripheral blood mononuclear 
cells (PBMC) isolated from peripheral blood samples taken from L-CTCL and 
GVHD patients pre- and post-ECP at Day 2, 1 month, 3 months, and 6 months, 
whenever possible.  The central hypothesis is that ECP works differently in 
L-CTCL and GVHD and that cyotoxic CD8+ T lymphocytes will be induced in 
L-CTCL whereas in GVHD T-regs will be induced. My specific aims were:  1) 
To determine the prevalence of functional CD4+CD25high/+Foxp3+ regulatory T- 
cells (T-regs) in clinically responsive L-CTCL patients after ECP treatment.  2) To 
determine the prevalence of functional CD8+ cytotoxic 'killer' T-cells in clinically 
responsive L-CTCL and GVHD patients after ECP treatment.  3) To characterize 
the dendritic cell (DC) subsets in L-CTCL and GVHD patients on ECP and 
determine a correlation in ECP-responsive patients.  The general rationale of this 
study is to identify the immune cell subsets that are efficacious in treating L-
CTCL or GVHD or that are associated with the immunological mechanism of 
ECP in L-CTCL versus GVHD patients ex vivo.  The significance of this study is 
to better understand how ECP works immunologically to improve treatment of 
patients.       
 
I tested this hypothesis and accomplished the proposed objective by addressing 
the aforementioned specific aims.   
 
Specific Aim 1:  I determined the prevalence of regulatory T cells in L-CTCL 
patients and GVHD patients before and after treatment.  Percentages of 
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CD4+Foxp3+ were high in 7/9 L-CTCL (L-CTCL-High) patients and in 5/7 GVHD 
(GVHD-High) patients studied.  In 6/7 L-CTCL-High patients, percentages of 
CD4+Foxp3+ T cells correlated with percentages of malignant CD4+CD26- T cells 
suggesting that these malignant T cells have the T-reg phenotype.   Thus, it was 
determined there were 6 L-CTCL patients had the malignant T-reg phenotype 
and 3 L-CTCL patients did not have a malignant T-reg phenotype.  After 3 
months of ECP, the L-CTCL patients with a malignant T-reg phenotype had 
decreased CD4+CD26- tumor T cells and CD4+Foxp3+, CD4+Foxp3+CD25-, and 
CD4+Foxp3+CD25+ T cells whereas the non-malignant T-reg phenotype patients 
had no change.  In the GVHD patients, there was a decrease of CD4+Foxp3+ and 
CD4+Foxp3+CD25- T cells, and increase of CD4+Foxp3+CD25+ T cells after 3 
months of treatment.        
   
Specific Aim 2:  I confirmed the low levels of CD8+ T cells in 6 L-CTCL patients 
but high levels of CD8+ T cells in 3 GVHD patients before ECP.  After ECP, the 
CD3+CD8+, CD8+CD69+, CD8+IFN-y+ T cells increased after 1 month in L-CTCL 
patients, but decreased in GVHD patients.   
 
Specific Aim 3:  I confirmed that DCs were low in L-CTCL and GVHD patients 
before treatment.  Numbers and percentages of mDCs and pDCs increased in L-
CTCL and GVHD patients after ECP treatment.  CSSMs increased on mDCs and 
pDCs.  In L-CTCL patients, numbers and percentages of activated mDCs were 
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increased within some responders.  However, in GVHD patients, there were 
increased numbers and percentages of pDCs. 
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CHAPTER 2 
EFFICACIES OF EXTRACORPOREAL PHOTOPHERESIS IN 
PATIENTS WITH L-CTCL AND GVHD IN THIS STUDY   
2.1 Background and Rationale 
ECP is extremely well-tolerated with minimal side effects, improves patients’ 
quality of life, and increases overall survival [83].  In CTCL patients, the overall 
response rate is between 54% and 66% with a 14%-33.3% complete response 
rate [85,116].  In GVHD patients, 76% of patients had improved skin 
manifestations with 38% complete responses [117].    
To achieve more complete responses, biological response modifiers 
(BRM) are administered with ECP in L-CTCL patients.  Since ECP+BRM affect 
the immune system, its immunologic mechanism(s) of action in vivo is of interest 
and is not fully understood in L-CTCL patients.  
L-CTCL patients have both blood and skin symptoms.  Malignant cells, 
CD4+CD26- T cells, are circulating in blood impairing immunity and the skin is 
erythrodermic.   Laboratory studies to enumerate these clinical presentations are 
used.  By flow cytometry, absolute numbers and percentages of CD4+CD26- T 
cells can be measured in blood samples at baseline and following ECP therapy.  
Skin involvement is calculated using a modified severity weighted assessment 
tool (mSWAT) score that measures the extent and severity of skin involved in 
patch, plaque, and tumor.  In this study, these two parameters, numbers of 
CD4+CD26- T cells and mSWAT score, were used to clinically assess disease 
progression or regression.  Therefore, during ECP therapy both blood and skin 
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improvements were assessed by one physician (M. Duvic) in L-CTCL patients.  
Skin response was defined as a > 50% decrease in the mSWAT score at 
baseline.  Response in the blood was subsets or the TCR Vβ clone, where 
available. 
2.2 Patients and Methods 
Please see Chapter 7. 
2.3 Results  
Eighteen L-CTCL patients completed the 6-month treatment course.  Their 
individual characteristics and responses are shown in Table 2.1.  Demographics 
and response rate are summarized in Table 2.2.  The cohort consisted of more 
Caucasians (16/18, 88.9%) and males (13/18, 72.2%) with a median age of 67.0 
(54-79) years.  All patients had ≥ 39.0 mSWAT except pt. # 17 who had normal 
skin (mSWAT 5.0).  Confluent erythema (≥ 87.0 mSWAT) was observed in 7 
patients who met the criteria for SS.  According to the revised criteria for MF/SS 
staging by ISCL/EORTC, 16/ 18 patients were diagnosed with MF/SS stage IV 
(8-SS IVA and 8-SS IVB) and 2 were staged as MF/SS IIIB.  Patient #8 had 
MF/SS stage IIIB in addition to chronic GVHD.  With the exception of patient #4 
(20.6%), all patients had ≥ 50% circulating CD4+CD26- tumor T cells.  Fifteen of 
18 patients (83.3%) had B2 (High tumor burden, >1000/μL CD4+ CD26- T cells) 
and 3/18 (16.7%) had B1 (Low tumor burden, <1000/μL CD4+CD26- T cells).  In 
16/18 patients, dominant TCRvβ clones were identified. 
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All L-CTCL patients were previously treated with skin directed therapies, 
but none were treated with radiation, chemotherapy, or immunosuppressive 
agents.   
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Table 2.1. Clinical summary of L-CTCL patients on extracorporeal 
photopheresis 
 
yrs = years, M=male, F=female, C=Caucasian, AA-African American, MR=minimal response, SD=stable disease, PR=partial 
response, PD=progressive disease,TCR=T-cell receptor, pts=patients, BM=bone marrow, GVHD=Graft-versus-host disease, 
SS=Sézary Syndrome, MF=Mycosis Fungoides, HTLV=Human T Lymphotrophic Virus, n/d = not done, mSWAT=modified 
severity weight assessment tool, ECP=Extracorporeal photopheresis 
 
*CD4+CD7- T cell phenotype present instead of CD4+CD26-. 
** Patient with both GVHD and MF/SS who underwent the greatest number of ECP cycles (25). 
***Patient with normal skin and malignant T-reg phenotype CD4+Foxp3+  (Shiue, LH et al 2012) 
 
 
Pt.# Age/Gender/Race Stage ECP Cycles Additional Therapy TCR vβ%   Skin mSWAT Blood CD4+CD26-T cells   Response     % μL Skin Blood Overall 1 58/F/C SS IVA 7 Bexarotene IFN-α Vβ (70.0) 63.0 64.2  1751.0 MR SD MR 2 66/M/C SS/MF IIIB 10 Bexarotene IFN- α Vβ22 (91.0) 100.0 82.2 413.0 PR CR PR 3 71/M/AA SS IVB (HTLV+) 7 Bexarotene IFN- α None 100.0 55.5 525.0 SD PD PD 4 54/M/C MF IVA 7 None Vβ17 (54.0) 39.0 20.6  69.0 SD SD SD 5 74/F/C SS IVB 11 Bexarotene Vβ (85.0) 93.0 89.9  3928.0 PR SD PR 6 74/M/C MF/SS IVB (BM+) 7 None  Vβ8 (73.7) 74.0 73.7 2218.0 MR PR PR 7 67/M/C SS IVA 12 Bexarotene Vβ (83.0) 87.0  79.1 1671.0 PR SD PR 8** 61/M/C GVHD, MF/SS IIIB 25 IFN-α Vβ (76.0) 77.0 64.4 227.0 SD MR MR 9 66/F/C SS IVB 13 Bexarotene IFN-α Vβ2 (97.0) 100.0 93.8  17981.0 SD SD SD 10 74/M/C SS/MF IVA 11 None Vβ7.2 (93.0) 48.1 85.9  2752.0 PR SD PR 11 79/M/C SS IVB (BM+) 9 Bexarotene Vβ 13.6 (97.1) 54.0 87.5 11581.0 PR SD PR 12* 71/M/C SS/MF IVA 10 Bexarotene IFN-α Vβ 17 (94.0) 100.0 56.0 1284.6 SD PD PD 13 78/F/AA SS IVB 10 None Vβ 13.6 (95.0) 47.0 94.5  9977.0 PD SD PD 14 63/M/C SS IVB (BM+) 10 IFN-α Vβ (94.0) 49.0 94.7  22751.0 PR SD PR 15 73/M/C SS IVA 10 Bexarotene Vβ 18.0 (95.0) 47.0 77.1  2600.0 SD SD SD 16 67/F/C SS IVA 6 Bexarotene n/d 67.0 91.9 4300.0 PR SD PR 17*** 63/M/C SS IVA 6 None Vβ 5.1 (95.0) 5.0 91.7 5139.0 MR SD MR 18 61/M/C SS IVB 8 None Vβ 7.1 (97.0) 87.0 91.7  5500.0 MR SD MR 
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Table 2.2.  L-CTCL Patient demographics and response rate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic L-CTCL (n=18) 
Gender Male (n=13, 72.2%) 
Female (n =5, 27.8%) 
Median Age (range) 67 (54-79) years 
 
Race Caucasian (n=16, 88.9%) 
African American (n=2, 11.1%) 
 
Stage-no. of patients (%) 
 
SS/MF IIIB-11.1% 
SS/MF IVA-44.4% 
SS IVB-44.4% 
 
Tumor burden (TB) 
 
 
TCRVβ+ pts (%) 
 
High TB (>1000/μl) 83.3% 
Low TB (<1000 /μl) 16.7% 
 
88.9% 
 
Median ECP cycles after 6 
mos (Range) 
 
9.9 (6-25) 
Response - no. of pts (%) 
Complete response (CR) 
Partial response (PR) 
Minor response (MR) 
Stable disease (SD) 
Progressive disease (PD) 
Deceased 
 
none 
n=8 (44.4%) 
n=4 (22.2) 
n=3 (16.7%) 
n=3 (16.7%) 
none 
 
Combination therapies ECP alone (n=6) 
ECP + Bexarotene (n=5) 
ECP + IFN-α (n=2) 
ECP+ Bexarotene+IFN-α (n=5) 
 
66.7% 
Response 
Rate 
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At recruitment, all patients were beginning ECP for the first time.  Six of 18 
L-CTCL patients were treated with ECP only.  For lack of response, biological 
response modifiers were added at 3 or more months after initial ECP.  Five 
received only Bexarotene at 150 or 225 mg per day, two received only interferon 
alpha at a dose of 3 milllion daily or three times per week (+IFN-α), and five 
received both Bexarotene and IFN-α.  The average number of ECP cycles 
administrated to L-CTCL patients was 9.9 over a six-month treatment period.   
At the end of study or 6 months, the overall response rate to ECP was 
66.7%,(12/18) with 8 patients achieving partial responses (PR, 44.4%) and 4 with 
minor responses (MR, 22.2%). There were no complete responses.  The non-
response rate was 33.3% (6/18) with 3 patients having stable disease (SD, 
16.7%) and 3 with progressive disease (PD, 16.7%). Responses were 
determined by changes in mSWAT scores (Figure 2.1A) and/or circulating 
CD4+CD26- tumor T cells (Figure 2.1B) from baseline shown for all patients.   
At baseline, there were no significant differences in mSWAT between 
responders and non-responders.  Similarly, at baseline, there were no significant 
differences in CD4+CD26- T cells between responders and non-responders.  
After 6 months, there was a decrease in CD4+CD26- T cells in both responders 
(Figure 2.1C) and non-responders (Figure 2.1D).  The mSWAT significantly 
decreased in responders (67.023.7, p=0.0004) but not in non-responders 
(72.273.4, p=0.63).   
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Figure 2.1 
A B 
C D 
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Figure 2.1. Clinical skin (mSWAT) and blood response (CD4+CD26- T cells) 
from baseline (BL) to 6 months (6M) of ECP-BRM therapy  
 
A) Percentage change in mSWAT from baseline (BL) to 6 months (6M) in all 
18 patients.   
B) Percentage change in CD4+CD26- T cells/μL from baseline (BL) to 6 
months (6M) in all 18 patients. 
C)  Skin (mSWAT, ▲) and blood (CD4+CD26- T cells/μL, ■) response at 
baseline (BL), 1 month (1M), 3 months (3M), and 6 months (6M) in 12 
responding patients.   
D) Skin (mSWAT, ▲) and blood (CD4+CD26- T cells /μL, ■) response at BL, 
1M, 3M, and 6M in 6 non-responding patients.  
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Eleven GVHD patients summarized in Table 2.3 who enrolled in this study 
had either a non-L-CTCL primary lymphoma or leukemia.  They developed acute 
and chronic GVHD after matched non-ablative stem cell transplantation.  All 
patients had skin involvement, and all received standard immunosuppressive 
therapy for GVHD in addition to ECP.  GVHD patients received an average of 
14.6 to 29.9 cycles of ECP treatment in a 3 to 6-month period.  After 3 to 6 
months treatment, 6 of 11 (54.5%) had achieved skin and/or other organ 
improvements (Table 2.4). 
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Table 2.3. Clinical summary of GVHD patients on extracorporeal photopheresis 
GVHD 
Patient 
# 
Age/Sex/
Race 
Primary Disease  Type of 
Donor  
Type of 
GVHD 
Organs affected Concurrent 
therapies 
ECP cycles at 
3/6 months 
Clinical Response at 3 
months 
Clinical response at 6 
months 
1 60/F/C NHL Match unrelated De novo chronic  Skin (sclerodermoid), Mouth Tacrolimus Methylprednisolone 7/12   No Response GVHD progression 
2 50/M/C NHL Match related sibling Acute, Grade 4 of skin Skin Steroids, Mycophenolate, Methylprednisolone 
5/n/a stopped ECP Skin-Partial response  n/a 
3 29/M/C CLL Cord blood  Late acute  Skin (non-sclerodermoid),  Gastrointestinal Mycophenolate, Prednisone, Tacrolimus 14/25 No response Partial response 
4 52/M/C CML Match related transplant Classic chronic Skin (sclerodermoid), eyes, liver, lung Steroids, Erythromycin, Prednisone  9/25 Stable disease Eye-no response Skin-no response Lungs-partial response Liver-complete response Overall-partial response 
5 62/M/C CLL Match unrelated Classic Chronic  Skin(sclerodermoid), liver, ,oral, eyes Tacrolimus 19/43 Skin-Partial response Liver-Complete response Eye-no response Mouth-partial response 
Skin - Partial response Liver-Complete response Eye -no response Mouth-partial response  
6 55/F/C SLL Match Related Donor-from male donor 
Classic chronic Skin(sclerodermoid), joints- fascia, mouth, liver, eye Tacrolimus, Methylprednisolone 23/37 Skin-Progression Eye-Progression Liver-normal Skin-minor response fascia -Improved Mouth-partial responses 
7 50/M/C CLL Match related donor Overlap syndrome (both chronic & acute) 
Skin (scleroderma), fascia, liver, mouth  Mycophenolate , Methylprednisolone, Imatinib, Tacrolimus 
n/a Skin-Partial response Fascia-Partial response Liver-Complete response Mouth- Complete response 
Skin-Partial response Fascia-Partial response Liver-Complete response Mouth- Complete  response 
8 23/M/C Aplastic anemia Match related Late acute Liver, skin-involved but not active  Methylprednisolone, Tacrolimus 14/n/a stopped ECP No Response No response-progression 
9 55/F/C AML Match related Classic chronic Skin, fascia, liver, Gastrointestinal  tract (acute) Prednisone, Tacrolimus,       11/35 No response No response 
10 52/M/C HL B cell lymphoma HLA matched sibling De novo chronic  skin (sclerodermoid),  Mouth, eye, lung Steroids,  Azithromycin 21/32 Stable disease ( Skin, Eyes, Lung, Mouth)        Stable disease (Eyes, Lung) Partial response    (Skin, Mouth)       
11 62/F/C Myelodysplastic syndrome / follicular lymphoma 
Match-sibling Overlap syndrome-both acute & chronic  
Skin (sclerodermoid, macular popular) Tacrolimus, Methyl prednisone 23/30 Stable Disease  Stable Disease 
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GVHD: Graft versus Host Disease, F: Female, M: Male, C: Caucasian, ECP: Extracorporeal Photopheresis, n/a: not available, HL: Hodgkin’s Lymphoma, NHL=Non-Hodgkin’s Lymphoma, AML: Acute myelogenous leukemia, CLL: Chronic lymphocytic leukemia, CML: Chronic myelogenous leukemia, SLL=Small Lymphocytic Lymphoma 
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Table 2.4.  GVHD patients’ demographics and response rate. 
 
 
Characteristic  GVHD (n=11)  
Gender  Male (n=7, 63.6%)  
Female (n =4, 36.4%) 
Median Age (range)  52 (23-62) years  
Race  Caucasian (n=11, 100%) 
Type of GVHD-no. of patients 
(%)  
Acute-9.0%  
Late acute-18.2%  
Denovo, chronic-18.2%  
Classic Chronic-36.4% 
Overlap (Acute & Chronic)-18.2%  
Median ECP cycles (Range)  After 3 mos:  14 (5-23) 
After 6 mos:  31 (12-43)  
Response - no. of pts (%)  
Complete response (CR)  
Partial response (PR)  
Minor response (MR)  
Stable disease (SD)  
Progressive disease (PD)  
No Response (NR) 
Response not available 
 
none  
n=4 (36.4%)  
n=1 (9.0%)  
n=1 (9.0%)  
n=2 (18.2%)  
n=2 (18.2%) 
n=1 
 
Combination therapies  
 
ECP alone (n=0)  
ECP + Tacrolimus (n=8)  
ECP + Steroids (n=3)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54.5% 
response 
rate 
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2.4 Discussion & Conclusions 
 
Since 12 of 18 L-CTCL patients (66.7%) and 6 of 11 GVHD patients (54.5%) 
achieved clinical responses with ECP, this study further confirms the efficacy of 
ECP in treatment for L-CTCL and GVHD [85,116,117].  A confounding factor in 
this study is that 12 of 18 L-CTCL and all GVHD patients received additional 
immunomodulatory therapies initiated at 1 or 3 months after starting ECP.  These 
include Bexarotene and IFN-α in L-CTCL patients and steroids and Tacrolimus in 
GVHD patients. We therefore cannot rule out effects of these agents on 
response and the modulation on DCs, T-regs, and CTLs in these patients.  
However, combined immunotherapy is widely used in both diseases, and a study 
devoid of these agents is not currently possible.  Of interest, 4 of 6 (66.7%) L-
CTCL patients who received ECP alone and 8 of 12 (66.7%) who received ECP 
with immunomodulatory therapy achieved the same overall clinical response 
rates, suggesting that most of the beneficial response may be attributed to ECP.   
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CHAPTER 3 
EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON REGULATORY T 
CELLS IN PATIENTS WITH L-CTCL AND GVHD 
3.1. Background and Rationale   
Regulatory T cells (T-reg) are immunosuppressive T cells that regulate 
immune reactions. The CD4+ Foxp3+CD25+ T-reg phenotype is the most 
understood type, but other phenotypes exist. CD4+Foxp3+ T cells were termed 
“naturally occurring” T-regs to distinguish them from in vitro generated 
“suppressor cells” [118].  A recent study reported that CD4+ Foxp3+CD25- T cells 
found in the periphery are reservoirs of inactive T-regs ready to activate when 
necessary [119].  
Because of the existence of multiple T-reg phenotypes, data on T-regs in 
L-CTCL are limited and controversial.  Both T-regs and L-CTCL cells share 
similar characteristics.  They are both CD4+ and anergic T cells.  Therefore, it is 
thought that the L-CTCL malignant clones may be T-regs.  Whether L-CTCL 
tumor cells are T-regs or not or if there is heterogeneity among L-CTCL patients 
is unclear.  As an expansion of anergic CD4+ T cells, MF/SS tumor cells 
suppress anti-tumor immunity and secrete Th2 cytokines [69,72,73].   Heid et al 
found a subset of SS patients with malignant suppressive CD4+ Foxp3+CD25- T 
cells and reported that tumors may be T-regs [50]. Conversely, in other studies, 
the T-reg phenotype was absent in L-CTCL [70,71,120].    
ECP has been hypothesized to induce T-regs in both 
autoimmune/inflammatory diseases and in Graft-versus-Host Disease (GVHD); 
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however, it is unknown if T-regs are also induced by ECP in L-CTCL patients.  To 
address this question, we examined three Foxp3+ T cell subsets in L-CTCL and 
GVHD patients before and after ECP treatment at Day 2, 1 month, 3 months, and 
6 months-2 years.  We investigated CD4+Foxp3+, CD4+ Foxp3+ CD25-, and CD4+ 
Foxp3+CD25+ T cells within peripheral blood mononuclear cells (PBMCs) by 
immunofluorescence flow cytometry and Foxp3 mRNA within PBMCs by 
quantitative real time PCR.   
3.2  Patients and Methods 
Please refer to Chapter 7  
3.3 Results 
 
Patients and clinical response  
Please refer to Chapter 2 
CD4+ Foxp3+ CD25- and CD4+Foxp3+CD25+ T cell subsets differ in patients 
with L-CTCL and GVHD at baseline.  
Percentages of CD4+Foxp3+ T cells were significantly higher than normal 
(8.3±2.6%) in both L-CTCL and GVHD.  Between the L-CTCL (n=9, 66.8±41.2%, 
p=0.03) and GVHD (n=7, 66.2±42.0, p=0.05) patients, percentages of 
CD4+Foxp3+ T cells were similar (Figure 3.1A).  Although percentages of 
CD4+Foxp3+ T cells were similar in L-CTCL and GVHD, percentages of CD4+ 
Foxp3+CD25- and CD4+ Foxp3+CD25+ T cell subsets differed between the 
disease groups.  Percentages of CD4+ Foxp3+CD25- T cells were higher in L-
CTCL (48.5±32.3%) versus GVHD (22.9±25.3%) patients (Figure 3.1B) whereas 
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CD4+ Foxp3+CD25+ T cells were significantly lower in L-CTCL (17.2±18.1%, 
p=0.04) versus GVHD (47.1±36.1%) patients (Figure 3.1C).  
The percentages of CD4+Foxp3+ T cells within L-CTCL patients were 
either higher (L-CTCL-High, 85.5±20.8%, n=7) or lower (L-CTCL-Low, 1.4±1.1%, 
n=2) than normal donors (ND) (Figure 3.1D).  No L-CTCL patients were within 
normal range (5.7-10.9%).  Within GVHD patients, percentages of CD4+Foxp3+ T 
cells were significantly higher than normal in 5/7 patients (GVHD-High, 
90.6±5.7%, p=4.5*107), lower than normal in 1/7 patients (GVHD-Low), and 
normal in 1/7 patients (GVHD-Normal) (Figure 3.1E).  Interestingly, 77.8% (7/9) 
of L-CTCL patients (L-CTCL-High) and 71.4% (5/7) of GVHD patients (GVHD- 
High) had significantly higher than normal percentages of CD4+Foxp3+ T cells 
(Figure 3.2C).  
 
CD4+ Foxp3+CD25- and CD4+ Foxp3+CD25+ T cell subsets differ between the 
L-CTCL-High and GVHD-High patients   
Since the majority of L-CTCL and GVHD patients had high percentages of 
CD4+Foxp3+ T cells, we next compared the CD4+Foxp3+CD25- and 
CD4+Foxp3+CD25+ T cell subsets between the L-CTCL-High and GVHD-High 
patients. L-CTCL-High patients (62.1±20.5%, p= 0.03) had significantly higher 
percentages of CD4+ Foxp3+CD25- T cells than GVHD-High patients 
(27.4±25.4%) (Figure 3.2B,D). In contrast, percentages of CD4+ Foxp3+CD25+ T 
cells were significantly lower in L-CTCL-High patients (22.1±17.7%, p=0.009) 
compared to GVHD-High patients (63.6±27.5%) (Figure 3.2B, E).  These data 
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suggest that L-CTCL and GVHD patients may be harboring pathogenic Foxp3+ 
phenotype cells prior to treatment. 
  
Malignant T cells with a Foxp3+ phenotype in 6/7 L-CTCL-High patients at 
baseline 
Whether the tumor cells are Foxp3+ regulatory T cells (T-regs) in at least 
some L-CTCL patients is controversial.  Berger et al reported that L-CTCL is a 
malignancy of T-regs [69], but other studies show a lack of malignant T cells with 
a Foxp3+ phenotype in majority of L-CTCL patients [70,71,73].  In our study, we 
investigated 9/18 patients’ T-reg phenotypes and their correlation to malignant T-
cell populations as defined by their expression of CD4+CD26-  [121].   
We found that patients with greater than 50% of CD4+CD26- T cells also 
had greater than 50% of CD4+Foxp3+ T cells.  There is a correlation between 
CD4+ Foxp3+ and CD4+ Foxp3+ CD25- T cells and malignant CD4+CD26- T cells 
in 6/7 L-CTCL-High patients (Figure 3.3A), but no correlation in 1 L-CTCL-High 
and the 2 L-CTCL-Low patients (Figure 3.3B).  As expected, the percentages of 
malignant cells and CD4+Foxp3+ T cells positively correlated within L-CTCL High 
patients (R=0.54) (Figure 3.3C).  There was also a positive correlation between 
percentages of malignant cells and CD4+Foxp3+CD25- T cells (R=0.58) 
suggesting that these malignant cells have a Foxp3+ phenotype but CD25 
negative (Figure 3.3D).  There was a negative correlation between malignant 
and CD4+ Foxp3+CD25+ T cells (R=-0.34) (Figure 3.3E).   All T cell percentages 
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and numbers in these L-CTCL-High and L-CTCL-Low patients are summarized in 
Table 3.2. 
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Figure 3.1. Foxp3+ T cells in L-CTCL and GVHD patients. 
A) Dot graph displaying the percentages of CD4+Foxp3+ T cells in L-CTCL and 
GVHD patients at baseline. 
B) Dot graph displaying the percentages of CD4+ Foxp3+CD25- T cells in L-
CTCL and GVHD patients at baseline.  
C) Dot graph displaying the percentages of CD4+ Foxp3+CD25+ T cells in L-
CTCL and GVHD patients at baseline.   
D) Dot graph displaying the percentages of CD4+Foxp3+ T cells in L-CTCL 
patients with High (L-CTCL-High) and Low Foxp3 (L-CTCL-Low) at 
baseline. 
E) Dot graph displaying the percentages of CD4+Foxp3+ T cells in GVHD 
patients with High (L-CTCL-High), Low (L-CTCL-Low), and Normal (L-
CTCL-Normal) Foxp3 at baseline. 
 
* denotes statistical significance, p-value<0.05 
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Table 3.1. T lymphocyte parameters in normal donors (ND) versus L-CTCL 
versus GVHD patients before ECP. 
 
 
 
 
 
 
 
 
 
 
p-value between L-CTCL and GVHD 
*= p<0.05 compared to normal 
 
 
 
 
 
 
 
 
 
 
 
 
ND 
(n=3) 
L-CTCL  
(n=9) 
GVHD 
(n=7) 
 
p-value 
CD4+Foxp3+ (μl) 9.9±7.9 3640.7±7226.2 76.0±158.9 0.22 
CD4+Foxp3+ (%) 8.3±2.6 66.8±41.2* 66.2±42.0* 0.98 
CD4+ Foxp3+ CD25-(μl) 3.7±4.2 3067.7±6126.9 40.3±95.9 0.22 
CD4+ Foxp3+ CD25-(%) 2.6±3.5 48.5±32.3* 22.9±25.3 0.13 
CD4+ Foxp3+CD25+(μl) 10.6±11.9 555.9±1079.5 36.4±65.6 0.2 
CD4+ Foxp3+ CD25+(%) 7.7±2.4 17.2±18.1 47.1±36.1 0.05 
CD4+CD25high (μl) n/a 285.8±569.3 n/a n/a 
CD4+CD25high (%) 0.6±0.5 3.2±5.4 9.6±6.0 0.07 
Foxp3 mRNA 0.9±0.5 27.0±48.9* 0.1±0.1 0.30 
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Table 3.2. T lymphocyte parameters in normal donors (ND) versus L-CTCL- 
High versus L-CTCL-Low patients before ECP. 
p-value between L-CTCL High and L-CTCL Low 
*= p<0.05 compared to normal 
 
 
 
 
 
 
 
 
 
 
 ND (n=3) L-CTCL-High (n=7) L-CTCL-Low (n=2) 
 
p-value 
CD4+Foxp3+ (μl) 9.9±7.9 4674.2±8001.0 23.3±29.1 
 
0.0009 
CD4+Foxp3+ (%) 8.3±2.6 85.5±20.8* 1.4±1.1 0.5 
CD4+ Foxp3+ CD25-(μl) 3.7±4.2 3933.7±6790.7 36.8±49.1 0.5 
CD4+ Foxp3+ CD25-(%) 2.6±3.5 62.1±20.5* 0.98±0.7 0.005 
CD4+ Foxp3+CD25+(μl) 10.6±11.9 714.1±1192.5 1.86±2.5 0.4 
CD4+ Foxp3+CD25+(%) 7.7±2.4 22.1±17.7 0.2±0.2 0.1 
CD4+CD25high (μl) n/a 107.8±80.7 908.8±1247.3 0.07 
CD4+CD25high (%) 0.6±0.5 1.7±2.2 8.5±11.6 0.1 
Foxp3 mRNA 0.9±0.5 30.9±51.4 0.2 n/a 
CD4+CD26- (μl) n/a 5208.4±7933.0 6288.5±5216.3 0.8 
CD4+CD26- (%) n/a 78.4±14.8 85.8±12.3 0.5 
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Table 3.3. T lymphocyte parameters in normal donors (ND) versus GVHD-
High versus GVHD-Low versus GVHD-Normal patients before ECP. 
 
p-value between GVHD High and ND 
 
 
 
 
 
 
 
 
 
 
 
 ND (n=3) 
GVHD-High 
(n=5) 
GVHD-Low 
(n=1) 
 
GVHD- 
Normal 
(n=1) 
 
p-value 
CD4+Foxp3+ (μl) 9.9±7.9 106.2±184.1 0.2 
 
0.8 
 
0.4 
CD4+Foxp3+ (%) 8.3±2.6 90.6±5.7 92.2 10.3 4.5*10
7 
CD4+ Foxp3+ CD25-(μl) 3.7±4.2 56.4±112.5 0 0.03 0.5 
CD4+ Foxp3+ CD25-(%) 2.6±3.5 27.4±0.2 54.6 0.4 0.2 
CD4+ Foxp3+CD25+(μl) 10.6±11.9 50.9±74.4 0 0.9 0.4 
CD4+ Foxp3+CD25+(%) 7.7±2.4 63.6±27.5 38.7 12.0 0.01 
CD4+CD25high (μl) n/a n/a n/a n/a n/a 
CD4+CD25high (%) 0.6±0.5 10.4±6.6 n/a 6.3 0.001 
Foxp3 mRNA 0.9±0.5 0.1±0.03 n/a 0.3 0.02 
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Table 3.4.  T lymphocyte parameters in normal donors (ND) versus L-CTCL- 
High versus GVHD-High patients before ECP. 
 
 
p-value between L-CTCL-High and GVHD-High 
*= p<0.05 compared to normal 
 
 
 
 
 
 
 
 
 
 
 
ND  
(n=3) 
L-CTCL-High 
(n=7) 
GVHD-High  
(n=5) 
 
p-value 
 
CD4+Foxp3+ (μl) 9.9±7.9 4674.2±8001.0 106.2±184.1 
 
0.2 
CD4+Foxp3+ (%) 8.3±2.6 85.5±20.8* 90.6±5.7* 0.6 
CD4+ Foxp3+ CD25-(μl) 3.7±4.2 3933.7±6790.7 56.4±112.5 0.2 
CD4+ Foxp3+ CD25-(%) 2.6±3.5 62.1±20.5* 27.4±25.4 0.03 
CD4+ Foxp3+CD25+(μl) 10.6±11.9 714.1±1192.5 50.8±74.4 0.2 
CD4+ Foxp3+CD25+(%) 7.7±2.4 22.1±17.7 63.6±27.5* 0.009 
CD4+CD25high (μl) n/a 107.80.7 n/a n/a 
CD4+CD25high (%) 0.6±0.5 1.7±2.2 10.4±6.6* 0.009 
Foxp3 mRNA 0.9±0.5 30.9±51.4 0.07±0.03* 0.5 
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Figure 3.2. Division of patients based on baseline percentages of 
CD4+Foxp3+ T cells by flow cytometry.     
A)  Representative flow cytometry dot plots of CD4+Foxp3+ T cells (upper 
right quadrant) from a normal donor (ND, left), patient 5 (Pt. 5-CTCL-High 
CD4+Foxp3+ T cells, middle), and patient 6 (Pt. 6-GVHD-High CD4+Foxp3+ 
T cells, right).   
B) Representative flow cytometry dot plots of CD4+ Foxp3+CD25-T cells 
(upper left quadrant) and CD4+ Foxp3+CD25+T cells (upper right quadrant) 
from normal donor (ND, left), patient 5 (Pt. 5-CTCL-High CD4+Foxp3+ T 
cells, middle), and patient 6 (Pt. 6-GVHD-High CD4+Foxp3+ T cells, right).   
C) Patients were divided according to the percentages of CD4+Foxp3+ T cells 
in peripheral blood.  Dot plot displaying percentages of CD4+Foxp3+ T 
cells in normal donors (ND, n=3), CTCL-High (n=7), and GVHD-High 
(n=5). 
D) Dot graph displaying the percentages of CD4+ Foxp3+CD25-T cells in 
normal donors (ND, n=3), CTCL-High (n=7), and GVHD-High (n=5).   
E) Dot graph displaying the percentages of CD4+ Foxp3+CD25+T cells in 
normal donors (ND, n=3), CTCL-High (n=7), and GVHD-High (n=5).   
 
* denotes statistical significance, p<0.05 
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Figure 3.3.  Correlation analysis of Foxp3+ T cell subsets and malignant 
CD4+CD26- T cells in L-CTCL-High and L-CTCL-Low patients 
A) Comparison of percentages of malignant CD4+CD26- T cells and 
percentages of CD4+Foxp3+ T cells, CD4+ Foxp3+CD25- T cells, CD4+ 
Foxp3+CD25+T cells, and Foxp3 mRNA(from left to right) in the 6 L-CTCL- 
High patients.   
B) Comparison of percentages of CD4+CD26- tumor T cells and percentages 
of CD4+Foxp3+ T cells, CD4+ Foxp3+CD25-T cells, CD4+ Foxp3+CD25+T 
cells, and Foxp3 mRNA(from left to right) in the 2 L-CTCL-Low patients.  
C) Scatter plot revealing a positive correlation between CD4+CD26- T cells 
and CD4+Foxp3+ T cells in the 6 L-CTCL-High patients. 
D) Scatter plot revealing a positive correlation between CD4+CD26- T cells 
and CD4+ Foxp3+CD25-T cells in the 6 L-CTCL-High patients. 
E) Scatter plot revealing a negative correlation between CD4+CD26- T cells 
and CD4+ Foxp3+CD25+T cells in the 6 L-CTCL-High patients. 
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Decrease of malignant cells with Foxp3+ T-reg phenotype after treatment 
with ECP in L-CTCL patients  
We next studied the effects of ECP on CD4+Foxp3+, CD4+ Foxp3+CD25-, 
and CD4+Foxp3+CD25+ T cells in L-CTCL High (Table 3.5).  We found a 
decrease in percentages and numbers of CD4+Foxp3+ (Figure 3.3A), CD4+ 
Foxp3+CD25- (Figure 3.3B), and CD4+ Foxp3+CD25+ T cells (Figure 3.3C) in the 
L-CTCL-High through the treatment timepoints.  Six of the 7 L-CTCL-High 
patients have the malignant Foxp3+ phenotype and were responders to ECP 
treatment.  Therefore, this data show that these malignant Foxp3+ phenotype 
cells decrease with treatment suggesting that there is an association to 
response.   
 
Decrease of Foxp3+ T cells after treatment with ECP in GVHD patients 
In the GVHD-High Foxp3 patients, the effects of ECP on percentages and 
number of CD4+Foxp3+, CD4+ Foxp3+CD25-, and CD4+Foxp3+CD25+ T cells in 
GVHD-High patients are summarized in Table 3.6.  Percentages of CD4+Foxp3+ 
T cells remained the same after 3-4 months of treatment.  However, percentages 
of CD4+Foxp3+CD25- decreased while CD4+Foxp3+CD25+ T cells trended to 
increase after 3-4 months of treatment (Figure 3.3D-F).  There were 4/5 
responders within these patients.      
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Table 3.5.  Percentages (mean±SD) and numbers of T lymphocytes and Foxp3 mRNA in L-CTCL-High patients 
before and after ECP. 
 
 
 n/a: not available 
 
 
 
 BL D2 1M 3M-4M 6M-10M 1YR-2YR 
CD4+Foxp3+ (μl) 4674.2±8001.0 3300.9±3656.9 990.3±896.1 3015.6 314.9±521.2 5.05 
CD4+Foxp3+ (%) 85.5±20.8* 94.4±3.9 68.9±51.5 52.5±56.5 64.6±44.9 98.1 
CD4+CD25-Foxp3+ (μl) 3933.7±6790.7 2644.4±2866.5 1177.8±499.7 4991.8 357.5±493.1 2.3 
CD4+CD25-Foxp3+ (%) 62.1±20.5* 70.2±8.9 54.9±40.1 44.5±45.3 42.9±26.6 44.3 
CD4+CD25+Foxp3+ (μl) 714.1±1192.5 649.1±88.3 187.3±158.7 494.5±699.2 58.1±92.9 2.8 
CD4+CD25+Foxp3+ (%) 22.1±17.7 24.0±12.8 13.8±12.4 7.9±10.3 20.7±22.8 53.8 
CD4+CD25high (μl) 107.8±80.7 n/a 97.1±87.8 75.0±66.3 243.6±368.5 n/a 
CD4+CD25high (%) 1.7±2.2 2.1±1.9 1.1±0.6 1.2±0.7 3.4±3.9 n/a 
Foxp3 mRNA (n=7) 30.9±51.4 36.0±67.0 20.8±40.8 11.3±19.5 19.2±39.9 n/a 
CD4+CD26- (μl) 5208.4±7933.0 n/a 3878.3±5109.7 2318.6±2446.4 
 
2456.3±1907.0 n/a 
CD4+CD26- (%) 78.4±14.8 n/a 72.8±20.3 69.2±26.2 72.5±25.0 n/a 
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Table 3.6.  Percentages (mean±SD) and numbers of T lymphocytes and Foxp3 mRNA in GVHD-High patients before and 
after ECP. 
 
 
 n/a: not available 
* 
 
 
 
 BL D2 1M 3M-4M 6M-10M 1YR-2YR 
CD4+Foxp3+ (μl) 106.2±184.1 13.0±19.0 18 10.1±6.4 22.2 n/a 
CD4+Foxp3+ (%) 90.6±5.7* 57.7±51.3 85.9 96.0±2.1 86.2 n/a 
CD4+CD25-Foxp3+ (μl) 56.4±112.5 1.3±1.1 11.2 0.4±0.1 2.3 n/a 
CD4+CD25-Foxp3+ (%) 27.4±25.4 3.1±2.9 53.5 4.4±2.7 8.8 n/a 
CD4+CD25+Foxp3+ (μl) 50.8±74.4 12.3 ±17.9 7.4 9.7±6.3 19.9 n/a 
CD4+CD25+Foxp3+ (%) 63.6±27.5* 55.1±48.8 35.2 91.9±2.4 77.4 n/a 
CD4+CD25high (μl) n/a n/a n/a n/a n/a n/a 
CD4+CD25high (%) 10.4±6.6* 15.7±14.1 8.9±8.3 10.4±4.5 n/a n/a 
Foxp3 mRNA (n=3) 0.07±0.03* 0.05±0.02 0.05±0.02 0.05 n/a n/a 
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Figure 3.4.  Changes in numbers of Foxp3+ T cell subsets after ECP-BRM in 
L-CTCL-High and GVHD-High patients by flow cytometry. 
A) Dot graph displaying the percentages of CD4+Foxp3+ T cells in L-CTCL- 
High patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 months (3-
4M), and 6-10 months (6-10M).   
B) Dot graph displaying the percentages of CD4+ Foxp3+CD25- T cells in L-
CTCL-High patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 months 
(3-4M), and 6-10 months (6-10M).   
C) Dot graph displaying the percentages of CD4+ Foxp3+CD25+ T cells in L-
CTCL-High patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 months 
(3-4M), and 6-10 months (6-10M).   
D) Dot graph displaying the percentages of CD4+Foxp3+ T cells in GVHD-High 
patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 months (3-4M), 
and 6-10 months (6-10M). 
E) Dot graph displaying the percentages of CD4+ Foxp3+CD25- T cells in 
GVHD-High patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 
months (3-4M), and 6-10 months (6-10M).   
F) Dot graph displaying the percentages of CD4+Foxp3+CD25+ T cells in 
GVHD-High patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 
months (3-4M), and 6-10 months (6-10M).  
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Table 3.7. Summary of GVHD patients’ characteristics studied in this 
chapter.   
 
 
Parameters 
 
GVHD Patients (n=7) 
 
 
Disease 
 
NHL (n=2) 
CLL (n=3) 
CML (n=1) 
SLL (n=1) 
  
Type of GVHD Chronic GVHD (n=4) 
Acute GVHD (n=2) 
Overlap (n=1) 
  
Donor  Match Related (n=4) 
Match Unrelated (n=2) 
Cord (n=1) 
  
Organ affected  Skin (n=7) 
  
Prophylaxis for GVHD Tacrolimus +Methotrexate (n=5) 
  
Concurrent Therapies  ECP + Tacrolimus (n=5) 
  
Response   
At 3 months  PR (n=3); NR (n=2); SD (n=1); PD (n=1) 
At 6 months PR (n=5); PD (n=1); n/a (n=1) 
  
Longer Outcomes Deceased (n=5); Alive (n=2) 
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3.4. Discussion & Conclusions 
In this small study of 9 L-CTCL patients with leukemic blood involvement 
(L-CTCL) 6/9 or 66.7% were found to have a malignant T-reg phenotype cells 
that correlated with the CD4+CD26- Sézary cell phenotype.  Both populations of 
cells decreased after ECP+BRM treatments suggesting that the treatments 
favorably modulate peripheral blood levels of CD4+Foxp3+ T cells.  All 6 of the L 
CTCL patients whose blood had >80% CD4+Foxp3+ cells were also responders 
to ECP-BRM.  The other 3 patients did not have a malignant T-reg phenotype 
and did not respond.  We conclude that patients with malignant T-reg circulating 
cells should be treated differently than patients whose blood has non-malignant 
T-reg populations.  ECP+BRM is an effective therapy for malignant T-reg L-CTCL 
patients but may not be as effective in non-malignant T-reg L-CTCL patients.   
Surprisingly, 5/7 GVHD patients had high CD4+Foxp3+ T cells at baseline 
and 4/5 were responders.  These data suggest that GVHD patients may have 
had prior Foxp3+ pathogenic cells.  We hypothesized that the initial disease 
treated with transplantation may have been a malignancy of Foxp3+ T-regs.  Two 
of the 5 GVHD patients with high Foxp3 had Non-Hodgkin’s Lymphoma (NHL), 1 
had Chronic Lymphocytic Leukemia (CLL), 1 had Chronic Myelogenous 
Leukemia (CML), and 1 had Small Lymphocytic Lymphoma (SLL).  All the GVHD 
patients’ characteristics studied in this chapter are summarized in Table 3.7.  
Although the literature is scarce, it has been reported that there is a high 
frequency of T-regs in CLL patients and correlates with disease progression 
[122].  Our data suggest that the high Foxp3 T-regs found in these GVHD High 
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patients may be remanent of their initial disease prior to transplantation.  
However, they may play a role in GVHD pathogenesis and may inhibit the graft 
versus tumor effect.  This data challenges the current thought that T-regs may be 
beneficial for GVHD patients.  Further studies are needed.      
The immunosuppression in L-CTCL patients is attributed to many factors 
but can be mainly explained by the loss of T- cell repertoire [59]. Having both 
malignant clonal T cells that produce Th2 cytokines and T-reg type cells would 
severely inhibit normal immune processes such as cell mediated cytotoxicity.  
Although previous studies have found a lack of Foxp3 expression in L-CTCL 
patients [70,71,120], Heid et al first reported that clonal tumor cells with 
regulatory function express Foxp3 but lack CD25 typically found on CD4+ T-regs 
in 40% of Sezary patients [73].   Our findings agree with Heid that L-CTCL or SS 
tumor cells are Foxp3+CD4+ T cells lacking CD25, the alpha chain of the IL-2 
receptor.  CD25 is a widely accepted marker for T-regs, however, more recent 
studies have reported that Foxp3 is a more specific marker for T-regs especially 
for development of regulatory function.  Foxp3-transduced into CD4+CD25- T 
cells elicited suppression of T cell proliferation and autoimmune disease and 
inflammatory bowel disease in vivo [123].  Another study characterized T-regs in 
CD25-CD45RBlow CD4+ T cell population by Foxp3 expression and found their 
suppressive activity in vitro was similar to CD4+CD25+ T –regs [124].  Taken 
together, these studies indicate that expression of CD25 on CD4+ T cell is 
insufficient to identify a cell as a T-reg and Foxp3 may be the more dominant 
marker.  Thus, heterogeneity amongst cells with suppressive function may exist.    
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After ECP+BRM, 6 of 9 (66.7%) L-CTCL patients achieved clinical 
responses confirming the efficacy of ECP reported by others [85,116].  L-CTCL- 
High (n=7) had an 85.7% (6 of 7) response rate whereas L-CTCL-Low patients 
had a 0% response rate.  All the patients with >50% of CD4+Foxp3+ T cells that 
were comparable to CD4+CD26- T cells responded to ECP+BRM.  Responses to 
ECP were associated with reduction in the numbers and percentages of 
malignant CD4+ Foxp3+ T cells.   Although a lower response rate was observed 
in patients with a non-malignant Foxp3+ phenotype, their responses may be 
attributed to other mechanisms.  Increased cytotoxic activity may be responsible 
for early responses seen in the patients with non-malignant Foxp3+ phenotype as 
we observed an increase in numbers of CD8+IFN-γ+ T cells after 1 month of 
treatment.    
From these results, we found that patients can be divided into two groups: 
one with high CD4+Foxp3+ T cells and a second with low CD4+Foxp3+ T cells.  
Biological differences in these 2 cohorts suggest differences in treatment may be 
warranted.  Because Foxp3 may be a biomarker for malignancy in CTCL, 
therapies targeting Foxp3 may be a novel treatment approach.  Diagnostic tests 
to detect Foxp3 expression should be incorporated into standard care to identify 
patients with a T-reg phenotype.  In addition, patients should be monitored for 
treatment response by flow cytometry of peripheral blood instead of solely using 
response observed in the skin.  This study for the first time examines the 
immunobiological effects of ECP+BRM in L-CTCL patients with a malignant T-reg 
phenotype.  It provides information to improve diagnosis and treatment of 
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heterogeneous L-CTCL patients and suggest that L-CTCL patients with 
malignant T-regs are better responders to ECP+BRM than patients without 
malignant T-regs.  ECP+BRM may be a good treatment option in patients with 
malignant T-regs.                                                  
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CHAPTER 4 
 
EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON CYTOTOXIC T 
LYMPHOCYTES IN PATIENTS WITH L-CTCL AND GVHD PATIENTS 
 
4.1 Background and Rationale 
Cytotoxic T lymphocytes (CTL) are a subset of T lymphocytes that arise 
from common lymphoid progenitors differentiated from hematopoietic stem cells.  
CTL by definition express the CD8+ molecule with the T cell receptor and kills 
other immune cells.  They have been of immunologic interest for potential 
rejection of tumors and role in vaccination responses.  CTL cytotoxic function 
was first identified in 1968 using alloantigen-activated thymus derived cells [36].  
After their initial discovery, further research revealed specificity of CTL [125].  
This led to further exploration in vaccines where they may be induced to prevent 
infectious diseases and limit tumor formation and progression.   
At the molecular level, the cytotoxic function is mediated through 
exocytosis of cytotoxic granules and cytokine secretion in response to MHC class 
I antigenic peptides.  By way of T cell receptor and CD8 ligand docking on the 
target cell MHC class I+peptide, cytotoxic granules, perforin and granzymes, 
participate in lysing and killing the target cell [42,125].  Perforin granules 
perforate the cellular membrane first and then release granzymes into the target 
cells.  This also causes the activation of the CD8+ T lymphocyte which induces 
the expression of CD69.  This transmembrane C-type lectin protein is involved in 
lymphocyte proliferation and is a receptor that transmits signals from outside to 
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inside the lymphocyte [39,40].  The cytokine, interferon-gamma (IFN-γ), is 
secreted in CD8+ T cells that have cytotoxic function [41,42].   IFN-γ is a type II 
IFN that signals through the JAK-STAT pathway and helps to promote an 
adaptive immune response against bacteria/viruses and tumors [43].  Thus, a 
current method of identifying CTL by flow cytometry is by intracellular expression 
of IFN-γ along with CD3, CD8, and CD69 markers [44-46].  
 Extracorporeal photopheresis, an immunomodulating therapy that induces 
lymphocyte apoptosis by UVA-psoralen, is used to treat cutaneous T cell 
lymphoma and graft-versus-host disease patients.  ECP is hypothesized to have 
an effect on CD8+ T cells in L-CTCL patients [108].  Prior to therapy, CD8+ T cells 
are abnormally low and L-CTCL patients with close to normal levels of CD8+ T 
cells do better on ECP [64].  Thus, it was hypothesized that ECP’s mechanisms 
of action is by the engulfment of apoptotic cells by antigen-presenting cells to 
induce or increase CTL and their activity [98].  However, in GVHD, CTL numbers 
are elevated and are thought to be primary mediators of disease yet ECP is 
clinically beneficial [112].  Thus, we hypothesize that ECP would decrease CTL 
numbers and their activity in GVHD.  Since it is currently unclear how ECP 
modulates CTL, we investigated its effects on CD8+ T lymphocyte numbers and 
their cytotoxicity in L-CTCL and GVHD patients.     
 
4.2 Patients and Methods 
 Please refer to Chapter 7. 
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4.3 Results 
Patients and clinical responses 
All L-CTCL (Table 2.1) and GVHD patients’ (Table 2.3) demographics and 
characteristics are reported.  The clinical characteristics and response rates of all 
L-CTCL and GVHD are summarized in Table 2.2 and 2.4.   
Based on sample availability, 6/18 L-CTCL patients and 3/11 GVHD 
patients were analyzed for CD3+CD8+, CD3+CD8+CD69+, and CD3+CD8+IFN-γ+ 
T cells.  The 6 L-CTCL patients’ demographics and characteristics are 
summarized in Table 4.1.  The 3 GVHD patients’ demographics and 
characteristics are summarized in Table 4.2.  The L-CTCL patients were 
diagnosed with Sézary Syndrome with a T cell receptor clone present in 5/6 
patients and one patient with late stage MF.  There was 1 patient (pt.12) who had 
a CD4+CD26+ T cell rather than CD4+CD26- population present.  Patients’ ages 
ranged from 58-79 years with a mean age of 70 years.  There were more males 
(n=4, 66.7%) than females (n=2, 33.3%) in this study.   Five out of six patients 
were concurrently on treatments with ECP.  They were either on Bexarotene or 
IFN-α or combination (Bexarotene+IFN-α).  Two patients (pt. #1 and #3) were 
treated with Bexarotene at the beginning of ECP treatment (study baseline).  The 
other patients had Bexarotene and/or IFN-α addition after 1 month of ECP 
treatment except pt #4.  Average number of ECP cycles at 6 months was 9.2 
(range 7-12).  All the GVHD patients had skin involvement.  Two patients were 
diagnosed with classic chronic GVHD and the other had late acute GVHD.  Ages 
ranged from 29-55 and the mean age was 45.3 years. There were more males 
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(n=2; 66.7%) than females (n=1, 33.3%).   GVHD patients were on combination 
therapies including Tacrolimus.  ECP cycles ranged from 25-37 at 6 months after 
initial ECP treatment.   
In SS patients, the blood responses measured by decreased CD4+CD26- 
T cell numbers are as follows: CR (n=0), PR (n=0), MR (n=0), SD (n=5), and PD 
(n=1).  The skin responses measured by decreased mSWAT are as follows:  CR 
(n=0), PR (n=1), MR (n=2), SD (n=2), PD (n=1).  The inclusion of skin and blood 
responses resulted in overall responses as follows:  CR (n=0), PR (n=1), MR 
(n=2), SD (n=1), PD (n=2).  Responders have CR, PR, MR, or SD.  Response 
rates were 83.3% for blood, 83.3% for skin, and 66.7% overall in SS patients.    
The responses were graded in the disease affected skin as a regression 
of erythroderma typical of cGVHD.  The overall response rate in this study was 
100% partial responders in GVHD patients.  Clinical characteristics for L-CTCL 
and GVHD patients are summarized in Table 4.3.      
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Table 4.1.  L-CTCL patients’ demographics and characteristics.  
Pt.= patient, F=Female, M=Male, C=Caucasian, AA=African American, ECP= Extracorporeal 
Photopheresis, n/a=not available, BM=bone marrow,TCR=T cell receptor, SS=Sezary Syndrome, 
MF=Mycosis Fungoides, IFN=interferon 
 
 
 
 
 
Pt. 
# 
Age/Sex/Race Diagnosis SWAT CD4+CD26- 
(%) 
TCR vβ 
(%) 
ECP 
cycles 
Concurrent 
Therapies 
1 58/F/C  SS IVA  63.0 64.2 
 
n/a  7 Bexarotene, 
IFN-α  
2 79/M/C SS IVB 
(BM+) 
54.0 87.5 
 
Vβ 13.6 
(97.1%) 
10 Bexarotene  
3 71/M/C SS/MF 
IVA 
100.0 56.0 
 
Vβ 17 
(94.0%) 
12 Bexarotene, 
IFN-α  
4 78/F/AA SS IVB 
(BM+) 
47.0 94.5 
 
Vβ 13.6 
(95.0%) 
10 none 
 
5 73/M/C SS  IVA 47.0 77.1 
 
Vβ 18.0 
(95.0%) 
9 Bexarotene  
 
6 61/M/C SS IVB 87.0 91.7 Vβ 7.1 
(97.0%) 
7 Bexarotene  
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Table 4.2.  GVHD patients’ demographics and characteristics. 
 
Pt. 
# 
Age/
Sex/
Race 
Disease 
Transplant 
done 
Type of 
Donor 
 
Type of 
GVHD 
 
Organs 
affected 
 
ECP 
cycles 
Concurrent 
Therapies  
 
1 29/M/
C  
CLL Cord Late 
aGVHD  
 
Skin (non-
sclerodermoi
d), GI (late 
aGVHD)  
 
25 Cellcept, 
prednisone 
(80mg, 2x 
daily), 
tacrolimus 
  
2 52/M/
C  
CML Match 
Related 
transplant  
 
Classic 
cGVHD 
(Progres-
sive 
cGVHD)  
 
Skin 
(scleroder-
moid, eyes, 
liver, lung  
 
25 Steroids, 
erythromycin, 
prednisone 
(60mg)  
 
3 55/F/C  SLL Match 
Related 
Donor-
from male 
donor  
 
Classic 
cGVHD-
prior hx 
of 
aGVHD  
 
Skin 
(scleroderm-
oid), joints-
fasicitis, 
mouth, liver, 
eye  
 
37 Tacrolimus 
(6mg), Medrol 
(16 mg)  
 
GVHD=Graft versus Host Disease, aGVHD= acute GVHD, cGVHD=chronic GVHD, F=Female, 
M=Male, C=Caucasian, ECP= Extracorporeal Photopheresis, n/a=not available, CLL=Chronic 
lymphocytic leukemia, CML=Chronic myelogenous leukemia, SLL=Small Lymphocytic Lymphoma 
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Table 4.3.  Clinical summary of L-CTCL and GVHD patients. 
 
 
 
 
Characteristic L-CTCL (n=6) GVHD (n=3) 
Sex Male (n=4, 66.7%) 
Female (n =2, 33.3%) 
Male (n=2, 66.7%) 
Female (n=1, 33.3%) 
 
Age (Mean) 70 (58-79) years 45.3 (29-55) years 
 
Race Caucasian (n=5) 
African Amer. (n=1) 
Caucasian (n=3) 
 
Diagnosis 
 
Sezary Syndrome IVA (n=3) 
Sezary Syndrome IVB (n=3) 
 
Late Acute GVHD (n=1) 
Classic Chronic GVHD (n=2) 
Tumor burden 
(TB) 
 
TCR vβ (≥95%) 
 
High TB (>1000/μl) 83.3% 
Low TB (<1000 /μl) 16.7% 
 
Yes (n=5, 83.3%) 
n/a 
n/a 
ECP cycles 
after 6 mos 
(Mean) 
 
 
9.2 (7-12) 29 (25-37) 
Clinical 
Response 
SD (n=5, 83.3%) 
PD (n=1, 16.7%) 
 
PR (100%) 
Combination 
therapies 
Bexarotene (n=5, 83.3%) 
IFN-α (n=2, 33.3%) 
Bexarotene+IFN-α (n=2, 33.3%) 
 
Tacrolimus (100%) 
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Low levels of CD3+CD8+, CD3+CD8+CD69+, and CD3+CD8+IFN-γ+ T cells at 
baseline in L-CTCL patients but high in GVHD patients 
Absolute values of CD8+ T cells subsets were compared between normal 
donors, L-CTCL, and GVHD patients at baseline prior to ECP treatment.  The 
absolute numbers of CD3+CD8+ T cells were statistically lowest (p<0.01) in L-
CTCL patients (n=6, 12.9±12.4 /μl) compared to normal donors (n=3, 596.6 ± 
412.8 /μl).  The highest absolute numbers were found in GVHD patients’ blood 
(878.9 ± 1513.6 /μl) (Figure 4.1A).  Similarly, CD3+CD8+CD69+ T cells were 
lowest in L-CTCL patients (6.3±6.5 /μl) compared to normal donors (288.5 ± 
185.6 /μl, p<0.01) and GVHD (758.8 ± 1314.0 /μl) patients (Figure 4.1B).  
Interestingly, the CD3+CD8+IFN-γ+ T cells were also lowest in L-CTCL patients 
(4.0 ±6.3) compared to normal donors (160.1±111.3, p<0.01) and GVHD patients 
(456.9±791.2) (Figure 4.1C), (Table 4.4).   
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Table 4.4.  Baseline numbers of CD8+ T cell subsets in normal donors 
and patients with L-CTCL and GVHD.   
 CD3+CD8+  
(/μl) 
CD3+CD8+CD69+  
(/μl) 
CD3+CD8+ IFN- γ+  
(/μl) 
Normal donor (n=3) 596.6 ± 412.8 288.5 ± 185.6 160.1±111.3 
L-CTCL (n=6) 12.9±12.4 6.3±6.5 4.0 ±6.3 
GVHD (n=3) 878.9 ± 1513.6 758.8 ± 1314.0 456.9±791.2 
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ND  GVHD 
* p<0.01 
Figure 4.1 
 
L-CTCL 
A 
B 
C 
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Figure 4.1.  Flow cytometry dot plots and graphs of numbers of CD8+ 
T cell subsets before treatment.  
A) CD3+CD8+ double positive T cells (top right quadrant) in a normal 
donor (ND), L-CTCL #1, and GVHD patient #3.   Graph (top right) 
shows absolute numbers of CD3+CD8+  T cells in normal and 
disease groups where black bars represent averages. 
B) CD3+CD8+CD69+  triple positive T cells (top right quadrant) in a 
normal donor (ND), L-CTCL , and GVHD patient.   Graph (middle 
right) shows distribution of absolute numbers of CD3+CD8+CD69+  
T cells in  normal and disease groups where the black bars 
represent averages. 
C) CD3+CD8+IFN-γ+ triple positive T cells (top right quadrant) in a 
normal donor (ND), L-CTCL, and GVHD patient.   Graph (lower 
right) shows distribution of absolute numbers of CD3+CD8+IFN-γ+ T 
cells in  normal and disease groups where the black bars represent 
averages.  
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Increase in CD3+CD8+, CD3+CD8+CD69+, CD3+CD8+INF-γ+ T cells after ECP 
treatment in L-CTCL patients  
 Five out of six L-CTCL patients had increased numbers of CD3+CD8+ and 
CD8+CD69+ T cells after one month and 3 months to 1 year.  On average, 
CD3+CD8+ and CD3+CD8+CD69+ numbers spiked at Day 2 (117.3 ±187.8, 89.5 
±146.0) and decreased after one month (101.7±196.6, 73.4±145.9) and 3 month-
1 year (60.3±123.3, 45.7±98.9).  Numbers were still higher than baseline 
(12.9±12.4, 6.3±6.5) after 3 months-1 year post-ECP (Figure 4.2A,B), (Table 
4.5).      
Four of the five patients with follow-up at one month had increased 
CD3+CD8+ IFN-γ+ T cells from baseline.  Three of the five patients with follow-up 
at 3 months-1 year also had increased CD3+CD8+IFN-γ+ T cells from baseline.  
On average, the numbers increased at Day 2 (7.8±7.4) and again at 1 month 
(9.6±11.5) but were lower at 3 months-1 year (3.7±7.0) and almost back to 
baseline levels (4.0±6.3) (Figure 4.2C), (Table 4.5).  
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Table 4.5.  Mean numbers of CD8+ T cell subsets pre- and post-ECP in L-
CTCL patients 
  Post-ECP p-value 
 Pre-ECP Day 2-1 week 1 M 3M-1YR  
CD3+CD8+ (/μl) 12.9±12.4 117.3 ±187.8 101.7±196.6 60.3±123.3 0.02 
CD3+CD8+CD69+  (/μl) 6.3±6.5 89.5 ±146.0 73.4±145.9 45.7±98.9 0.02 
CD3+CD8+ IFN- γ+ (/μl) 4.0±6.3 7.8±7.4 9.6±11.5 3.7±7.0 0.02 
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Figure 4.2 
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Figure 4.2.  Flow cytometry analysis of CD8+, CD8+CD69+, and CD8+IFN-γ+ T 
cells in L-CTCL patients (n=6) at baseline and after ECP+BRM treatment. 
Representative flow cytometry dot plots (left to right) from a responding L-CTCL 
patient #1 and dot graphs of absolute numbers of (far right) A) CD3+CD8+, B) 
CD8+CD69+, and C) CD8+IFN-γ+ T cells at baseline (BL), Day 2 (D2)-1week 
(1W), 1 month (1M), and 3 months (3M)-1 year (1YR).   
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CD3+CD8+, CD3+CD8+CD69+, CD3+CD8+IFN-γ+ T cells decreased in GVHD 
patients treated with ECP 
Three GVHD patients had follow-up time points at 3 months of ECP 
therapy.   All of them had decreased numbers of CD3+CD8+ and CD8+CD69+ T 
cells from baseline (878.9 ±1513.6, 758.8±1314.0) to post –ECP 3 months 
(1.8±2.4, 0.3±0.5).  On average, the CD3+CD8+ T cell levels decreased from 
baseline (878.9 ±1513.6) to day 2 (0.9±0.2) dramatically and remained low at 1 
month (10.02) , 3 months (1.8±2.4), and 6 months (60.9) post-ECP.  Similarly, on 
average, the CD3+CD8+CD69+ T cell levels dramatically decreased from baseline 
(758.8±1314.0) to day 2 ( 0.1±0.02) and remained low at 1 month (0.2), 3 months  
(0.3±0.5), and 6 months (32.4) post-ECP. 
CD3+CD8+IFN-γ+ T cells also decreased from baseline (456.9±791.1) to 3 
months (0.2±0.2) post-ECP in all the GVHD patients.  On average, the levels 
dramatically decreased from baseline (456.9±791.1) to Day 2 (0.1±0.0) and 
remained low at 1 month (0.08), 3 months (0.2±0.2), and 6 months (9.1) post-
ECP (Figure 4.3, Table 4.6). 
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Table 4.6.  Mean numbers of CD8+ T cell subsets pre- and post-ECP in 
GVHD patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Post-ECP 
 Pre-ECP Day 2 1 mo 3 mos 6mos 
CD3+CD8+ (/μl) 878.9 ±1513.6 0.9±0.2 10.02 1.8±2.4 60.9 
CD3+CD8+CD69+  (/μl) 758.8±1314.0 0.1±0.02 0.2 0.3±0.5 32.4 
CD3+CD8+ IFN -γ+ (/μl) 456.9±791.1 0.1±0.0 0.08 0.2±0.2 9.1 
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Figure 4.3 
 
 
 
 
 
 
 
98  
Figure 4.3.   Flow cytometry dot plots of numbers of CD8+ T cell subsets 
after treatment in GVHD patient #3 who responded.   
A) CD3+CD8+  double positive T cells (top right quadrant in each panel) at 
baseline (BL), 3 months (mos), and 6 mos post-ECP (top from left to right).    
B) CD3+CD8+CD69+  triple positive T cells (top right quadrant in each panel) 
at BL, 3 mos, and 6 mos post-ECP (middle from left to right).  
C) CD3+CD8+IFN-γ+ triple positive T cells (top right quadrant in each panel) at 
BL, 3 mos, and 6 mos post-ECP (bottom from left to right).  
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The correlation of CD3+CD8+IFN-γ+ T cells to clinical response in L-CTCL 
patients 
On average, the numbers of CD4+CD26- SS tumor cells decreased from 
baseline (6281.8 /μl), to 1 month (4440.5 /μl), and to 6 months (2354.4 /μl) in 
selected SS patients who had cells available for in vitro analysis (n=6).  However, 
numbers of CD3+CD8+IFN-γ+ T cells increased from baseline (3.99 /μl) to Day 2 
(7.77/ μl) to 1 month (9.56 /μl), but then decreased at 3 months-1 year (3.69 /μl) 
post-ECP (Figure 4.4A).  
This change in CD8+ cells were associated with improvement and 
worsening of skin involvement as determined by  mSWAT measurements of skin 
involvement.  Mean mSWAT scores decreased from baseline (68.0), to 1 month 
(45.7)  but increased again at 3 months -1 year (54.3) in these SS patients (n=6).  
There was an inverse relation between mSWAT improvement and increase in 
numbers of CD3+CD8+IFN-γ+ T cells suggesting that induction of CD8+ 
cytotoxicity favorably effects clinical L-CTCL expression.  (Figure 4.4B).   
There were 3/6 responders within the SS patients studied for activated 
and functional IFN-γ producing CD8+ T cells.  Responding 3 patients had higher 
numbers of CD3+CD8+ (23.7±3.5), CD3+CD8+CD69+ (11.5±2.8) and 
CD3+CD8+IFN-γ+ (7.7±4.4) T cells prior to treatment compared to the three non-
responders (2.1±0.6; 1.2±0.5; 0.3±0.2)  (Table 4.7).  Although, in non-responders 
there was an increase in numbers of CD8+ T cell subsets after treatment at 1 
month, the numbers of CD3+CD8+ (Table 4.8, 9.0±1.2), CD3+CD8+CD69+ (Table 
4.9, 4.5±1.2) and CD3+CD8+IFN-γ+ (Table 4.10, 2.2±0.8) remained low.  In 
100  
responders, the numbers of CD3+CD8+ (163.5±144.8, 6.9-fold, Table 4.8), 
CD3+CD8+CD69+ (119.3±107.5, 10.3-fold, Table 4.9), and CD3+CD8+IFN-γ+ 
(14.5±7.5, 1.9-fold, Table 4.10) were higher than non-responders and increased 
from baseline after only 1 month of ECP.  These results suggest that although 
these CD8+ subset numbers remained low, their activation status and cytotoxic 
function improved with ECP treatment and may be related to overall clinical 
response. 
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Figure 4.4  
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Figure 4.4.  Clinical response and CD3+CD8+IFN-γ+ cytotoxic T cells in L-
CTCL patients.   
A) Comparison of CD8+ IFN-γ+ T cells (dashed line) numbers to SS tumor 
cells, CD4+CD26-, (solid line) T cell numbers before and after treatment. 
B) Comparison of CD8+ IFN-γ+ T cells (dashed line) numbers mSWAT score 
(solid line) before and after treatment.  
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Table 4.7.  Comparison of CD8+ T cells in L-CTCL responders and 
non-responders at baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Responders 
(n=3) 
 
Non-responders 
(n=3) 
   
CD3+CD8+ 23.7±6.1 2.1±1.1 
CD8+CD69+ 11.5±4.8 1.2±0.9 
CD8+IFN-γ+ 7.7±7.7 0.3±0.3 
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Table 4.8.  Numbers of CD3+CD8+ T cells in L-CTCL responders 
and non-responders before and after treatment. 
 
 
 
 
BL 
 
D2-1W 
 
1M 
 
3M-1YR 
 
Responders (n=3) 
1 27.2 334.2 452.4 280.9 
11 27.2 n/a 0.5 2.6 
18 16.7 7.3 37.7 2.0 
Mean±SD 23.7±6.1 170.8±231.2 163.5±250.9 95.2±160.9 
 
Non-Responders (n=3) 
12 1.0 n/a n/a 10.3 
13 3.1 10.5 7.4 n/a 
15 2.3 n/a 10.5 5.9 
Mean±SD 2.1±1.1 10.5 9.0±2.2 8.1±3.1 
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Table 4.9.  Numbers of CD8+CD69+ T cells in L-CTCL responders and 
non-responders before and after treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BL 
 
D2-1W 
 
1M 
 
3M-1YR 
 
Responders (n=3) 
1 8.3 258.1 333.8 222.6 
11 17.1 n/a 0.3 0.2 
18 
9.2 4.7 23.8 0.1 
Mean±SD 11.5±4.8 131.4±179.2 119.3±186.1 74.3±128.4 
 
Non-Responders (n=3) 
12 0.2 n/a n/a 2.5 
13 1.8 5.6 3.0 n/a 
15 1.5 n/a 6.0 3.1 
Mean±SD 1.2±0.9 5.6 4.5±2.1 2.8±0.4 
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Table 4.10.   Numbers of CD8+IFN-y+ T cells in L-CTCL responders 
and non-responders before and after treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BL 
 
D2-1W 
 
1M 
 
3M-1YR 
 
Responders (n=3) 
1 0.6 16.3 25.8 16.12 
11 15.8 n/a 0.2 0.2 
18 6.6 3.4 17.5 0.09 
Mean±SD 7.7±7.7 9.9±9.1 14.5±13.0 5.5±9.2 
 
Non-Responders (n=3) 
12 0.17 n/a n/a 0.73 
13 0.7 3.6 1.2 n/a 
15 0.1 n/a 3.1 1.3 
Mean±SD 0.3±0.3 3.6 2.2±1.3 1.0±0.4 
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The correlation of CD3+CD8+IFN-γ+ T cells and clinical response in GVHD 
patients 
All three GVHD patients had decreased numbers of CD8+, CD69+ and 
IFN-γ+ T cells and were classified as partial responders to ECP.  Unfortunately, 
there were not enough samples to assess the non-responders’ CD3+CD8+ T cells 
levels and make a comparison.   
 
4.4 Discussion & Conclusions 
In this study, we report lower-than-normal baseline levels of CD3+CD8+, 
CD3+CD8+CD69+, and CD3+CD8+IFN-γ+ T cells in the blood of Sézary Syndrome 
(SS) patients.  This is consistent with previous findings of low levels of 
CD3+CD8+ T cells and their inability to produce IFN-γ cytokine in L-CTCL 
patients [103,126,127].  There are no reported studies on the levels of 
CD3+CD8+CD69+ or CD3+CD8+IFN-γ+ T cells in SS patients’ blood.  However, in 
GVHD patients, the levels of CD3+CD8+, CD3+CD8+CD69+, and CD3+CD8+IFN-
γ+ T cells were higher than normal at baseline which supports increased CD8+ 
Teffector  cells in cGVHD patients reported by Grogan et al in 2011 [128].  ECP 
action on CD8+ T cell subsets in L-CTCL and GVHD patients appear to have 
opposite effects but how this occurs is unknown.   
The major findings of this study are that CD3+CD8+, CD3+CD8+CD69+, 
and CD3+CD8+INF-γ+ T cell numbers increase after ECP treatment in L-CTCL 
patients but decrease in GVHD patients’ blood.  Our data suggest that ECP is 
improving not only the CD3+CD8+ T cell numbers but also their function as 
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determined by increased IFN-γ secretion in L-CTCL patients’ blood CD8+ T cells 
after 1 month of treatment.  This increase was found in L-CTCL patients who 
responded to ECP as measured by a decrease in the SS CD4+CD26- T cells and 
by decrease in the skin mSWAT score.  Surprisingly, the opposite effect occurred 
in the blood of GVHD patients.  Our results show that in GVHD patients, 
CD3+CD8+ T cell numbers are not only reduced but also the function as 
measured by IFN-γ is reduced by ECP.  Since GVHD is mediated by CD3+CD8+ 
T cells, it is logical that the reduction of these cells would occur in patient 
responders to ECP.     
These results suggest for the first time that ECP works by different 
mechanisms in improving L-CTCL and GVHD.  This paradox suggests a 
difference in ECP mechanism of action with different immunological states at 
baseline.  If ECP does not work the same way in these two diseases, it suggests 
that ECP has differential effects on immunity and works by tailoring to the 
immune disease state.   
A possible mechanism by which ECP is modulating CD3+CD8+ T cells in 
L-CTCL patients would be by antigen-presenting cell (APC) taking up 
UVA/psoralen (ECP) treated cells that are apoptotic.  This uptake of apoptotic 
cells provides a tumor antigen source for activation of CD3+CD8+ T cells to 
produce IFN-γ to elicit an anti-tumor immune response for down-regulation of 
tumor cells in L-CTCL. Since previous studies in GVHD suggest that CD3+CD8+ 
T cells are mediators of disease, the decrease of these Th1 producing cells 
would in turn cause disease regression in L-CTCL.  Thus, the mechanism of this 
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reduction of cells by ECP in GVHD patients may be by regulatory T cell 
suppression or cell death of CD3+CD8+ T cells by antigen-primed dendritic cells.    
In summary, these results support our hypothesis that CD3+CD8+ T cells 
are increased in numbers and activity in L-CTCL patients but are reduced in 
GVHD patients after ECP treatment.  This shows that the ECP mechanism of 
action is different depending on the disease state.  These findings are in a small 
study cohort and were limited by amount of frozen patient samples available 
before and after ECP.  Although this study cohort was small, the majority of the 
patients had similar trends.  Another limitation of this study is that some of the 
patients were on other treatments besides ECP.  Therefore, it is unclear if the 
induction of activated, IFN-γ producing CD3+CD8+ T cells were by ECP or by 
Bexarotene or IFN-α.  Thus, further study in a larger cohort with ECP as a 
monotherapy in addition to the investigation of CTL activity would be ideal.  
However, from this study we found for the first time a favorable increase in the 
function of CD8+ T cells after only 1 month of ECP in L-CTCL patients whereas a 
favorable decrease in numbers of functional CD8+ T cells in GVHD patients after 
treatment with ECP.  These data suggest that the mechanism of ECP action 
through CD8+ T cells is different in L-CTCL and GVHD patients.   
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CHAPTER 5 
EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON DENDRITIC 
CELLS IN PATIENTS WITH L-CTCL AND GVHD. 
 
5.1 Background and Rationale  
Like other immune cells that participate in the innate and adaptive immune 
response, DCs express distinct cell surface receptors or ligands to sense and 
respond to environmental stimuli. These cell surface signaling molecules (CSSM 
s) are vital for their differentiation, maturation, and function [129].  In the normal 
steady-state condition, DCs express low levels of CSSMs such as co-stimulatory 
and/or co-inhibitory molecules and MHC Class I and II molecules. This allows the 
immature DCs to maintain peripheral tolerance to self-antigens.  In the presence 
of danger signals (i.e. antigens and infections), there is an up-regulation of 
expression of CSSMs resulting in DC maturation and subsequently promoting T 
cell immunity [130].  The B7 family members including B7-1 (CD80), B7-2 
(CD86), and B7-H2 (the inducible costimulator ligand, ICOSL) are major 
members of CSSMs. They provide T-cell costimulatory/coinhibitory signals upon 
binding to their receptors CD28, CTLA-4 and ICOS, respectively [131].  
DCs are the most important initial source of cytokines governing the 
development of helper T cell (Th) responses. Two well described human DC 
subpopulations with different biological functions are: the CD11c+CD123- myeloid 
DCs (mDCs) and the CD11c-CD123+ plasmacytoid DCs (pDCs), which induce 
different types of Th cell responses based on environmental factors [8].  In 
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general, mDCs produce IL-12 and polarize naïve T cells toward a Th1 
phenotype, whereas pDCs stimulated with IL-3 produce low levels of IL-12 and 
large amounts of IFN-α and results in a Th2 response.  Moreover, ICOSL on 
pDCs is critical for inducing the immunosuppressive IL-10 cytokine which induces 
T-regs [8].  The up-regulation of Th1 cytokines and IL-12 is present in chronic 
GVHD and implicates a Th1-driven immunopathogenesis [132].   Modulation of 
DC subpopulations and a shift of cytokine profile from Th1 to Th2 in chronic 
GVHD patients have been observed following treatment with ECP [133]. In 
contrast, the impaired immunity in L-CTCL has been attributed to the over-
production of Th2 cytokines secreted by the malignant T cell clone(s) and down-
regulation of Th1 and cytotoxic responses [134].  Moreover, the low baseline 
mDCs and pDCs found in SS patients are associated with increased tumor 
burdens and advanced stages of L-CTCL [68].  Others have shown that the 
clinical and hematological Improvements are associated with a shift from Th2 to 
IL-12 and Th1 response in SS patients after ECP treatment [108].  We therefore 
postulated that the paradoxical effects of ECP in L-CTCL and GVHD might be 
explained if ECP were to modulate DC subpopulations in both diseases.   
In this prospective study, we studied the prevalence of mDCs and pDCs in 
peripheral blood by flow cytometry in 18 L-CTCL patients and 11 GVHD patients 
during ECP treatment.  HLA-DR (MHC class II) and co-stimulatory/co-inhibitory 
molecules were assessed by flow cytometry and quantitative real-time PCR.  We 
conclude that ECP modulates DC subpopulations’ numbers, ratios, and 
expression of CSSMs.  The correction of DC defects and balancing of DCs 
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towards a more normal status may contribute to the clinical efficacy of ECP in L-
CTCL and GVHD.  
5.2. Patients & Methods 
Please refer to Chapter 7. 
5.3. Results 
Low numbers of DC subpopulations in GVHD and L-CTCL patients increase 
after ECP 
Since defective blood DCs in L-CTCL and GVHD patients are thought to 
contribute to impaired immunity [68,135], we first determined the prevalence of 
Lin-HLA-DR+CD11c+ mDC and Lin-HLA-DR+CD123+ pDC in L-CTCL and GVHD 
patients at baseline and after ECP treatment.  
When compared to the numbers of mDC (0.64±0.15%) and pDC 
(0.68±0.50%) from normal donors (ND), GVHD patients had significantly lower 
numbers of both mDCs (0.10±0.11%, p<0.05) and pDCs (0.08±0.12%, p<0.01) at 
baseline (Table 5.1 & Figure 5.1A).  In contrast, DC numbers in L-CTCL patients 
were much more heterogeneous at baseline: 12 of 18 (66.7%) L-CTCL patients 
had lower than normal mDCs (0.24±0.16%, p<0.01) and 10 of 18 (55.6%) had 
lower than normal pDCs (10/18, 0.13±0.05%, p<0.01) (Table 5.2).  Those L-
CTCL patients with low pDCs also had low numbers of mDCs.   
One third of L-CTCL patients had normal DC counts (5/18, 27.8%, mDCs; 
7/18, 38.9%, pDCs).  Our data suggest that loss of mDCs and pDCs is profound 
in GVHD patients, and commonly occurs in L-CTCL patients.  
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Patient #17 with a T-reg phenotype, reported elsewhere [136], had high 
mDC and normal pDC numbers.  Clinically his skin looked normal but contained 
on biopsy atypical lymphocytes with epidermotropism consistent with MF. We 
hypothesized that the T-reg phenotype may suppress the inflammatory response 
causing characteristic MF erythema and scaling.  Patient #4 with high pDCs and 
normal count mDCs had the lowest tumor burden (20.6% CD4+CD26- circulating 
T cells) among all patients. 
After ECP treatment, there was a trend towards increasing numbers of 
mDCs and pDCs over 1-6 month period in 6 GVHD patients (Figure 5.1B, 
Figure 5.2B&D).  Similarly, 8 of 12 L-CTCL patients (66.7%) with low mDCs at 
baseline showed an increase in mDC numbers over 6 months of ECP treatment 
(Figure 5.1C, Figure 5.2A).  Four of 5 (80.0%) L-CTCL patients with normal 
mDC numbers before ECP also showed an increased in mDC numbers with 
therapy.  Patient#17 with a T-reg phenotype had high mDCs before ECP which 
increased even more after treatment.  On the other hand, 7 of 18 (38.9%) L-
CTCL patients had increased pDCs and 8 patients had decreased pDCs (44.4%) 
(Figure 5.1C, Figure 5.2C). In half of the L-CTCL patients with low pDC 
numbers before ECP, pDC numbers increased at 3 and 6 months after ECP (5 of 
10, 50.0%).  Four of 7 (57.1%) L-CTCL patients with normal baseline pDC 
numbers had decreased numbers during therapy.  Patient #4 with high pDCs 
before ECP had lower numbers after ECP.  Overall, in L-CTCL patients, the 
average mDC number was significantly increased at 6 months after ECP (p = 
0.0272) and the average DC number was marginally lower at 3 months after ECP 
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compared to baseline (p = 0.0944) (Table 5.3).  Our results suggest that after 
ECP, in GVHD patients, there is a trend towards increasing numbers of both 
mDCs and pDCs, whereas in most of L-CTCL patients there was a selective 
increase of mDCs and heterogeneous changes in the pDC numbers.  
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Table 5.1. Percentage, ratio, and HLA-DR expressions on mDCs and pDCs 
in peripheral blood of L-CTCL and GVHD patients  
 
 
 
†MFI: mean fluorescence intensity; ND: normal donors;* p<0.05; ** p<0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Percentages (%) Ratio HLA-DR expression (MFI)† 
 mDC pDC mDC/pDC pDC/mDC mDC pDC 
ND 
(n=3) 
0.64 ± 0.15 0.68 ± 0.50 1.34 ± 1.26 1.35 ± 1.08 
3956.41 ± 
1398.29 
1860.10 ± 
602.57 
GVHD 
(n=10) 
0.1 ± 0.11* 0.08 ± 0.12** 5.66 ± 4.55* 0.46 ± 0.52* 
2006.65 ± 
1157.27** 
1466.11 ± 
674.18 
L-CTCL 
(n=18) 
0.41 ± 0.32* 0.39 ± 0.48 1.39 ± 0.94 1.05 ± 0.79 
1919.62 ± 
965.76** 
1460.78 ± 
609.11 
117  
 
 
 
Table 5.2.  The numbers, ratios, and HLA-DR expression on mDCs and 
pDCs in L-CTCL patients 
 
 Percentages (%) 
 
 Ratio  HLA-DR 
expression (MFI)† 
mDC pDC mDC/pDC pDC/mDC mDC pDC 
L-CTCL-High 
No. of patients 
value 
 
1 
1.33 
 
1 
2.12 
  
3 
3.04±0.58 
 
3 
2.68±0.18 
  
0 
 - 
 
0 
 - 
L-CTCL–Normal 
No. of patients 
Value 
 
5 
0.65±0.08 
 
7 
0.50±0.16 
  
15 
1.06±0.57 
 
14 
0.76±0.27 
  
2 
3851.68
±9.19 
 
9 
2007.42
±498.81 
L-CTCL-Low 
No. of patients 
Value 
 
12 
0.24±0.16 
 
10 
0.13±0.05 
 
 
 
0 
- 
 
1 
0.27 
  
16 
1678.11
±702.52 
 
9 
984.16 
±199.66 
L-CTCL–High: L-CTCL patients with higher than normal levels; L-CTCL–Normal: L-CTCL patients with 
normal range levels; L-CTCL–Low: L-CTCL patients with lower than normal levels; †MFI: mean fluorescence 
intensity 
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Figure 5.1 
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Figure 5.1. Flow cytometry analysis of Lin-HLA-DR+CD11c+ mDCs and Lin-
HLA-DR+CD123+ pDCs in L-CTCL and GVHD patients before and after ECP.     
A) Freshly isolated PBMCs from normal donors (ND), L-CTCL patients, and 
GVHD patients were stained with 4-Color Dendritic Value Bundle kit, and Lin-
HLA-DR+CD11c+ mDC populations (upper panel, circled purple portions) and Lin-
HLA-DR+CD123+ pDC populations (lower panel, circled green portions)  were 
gated with Becton-Dickinson LSR II (BD Biosciences, San Jose, CA), and 
analyzed in FCS Express Version 3 (DeNovo software, Los Angeles, CA).  The 
representative flow plots from ND, GVHD patients, and L-CTCL patients with 
normal (L-CTCL-Normal) and low (L-CTCL-Low) counts were shown.  
B) The representative flow plots of Lin-HLA-DR+CD11c+ mDCs (upper panel) and 
Lin-HLA-DR+CD123+ pDCs (lower panel) were presented from GVHD patient #3 
at baseline (BL), Day 2, 1M, and 3M after ECP.  
C) The representative flow plots of Lin-HLA-DR+CD11c+ mDCs (upper panel) and 
Lin-HLA-DR+CD123+ pDCs (lower panel) were from L-CTCL Patient #11 at BL, 
Day 2, 1M, 3M, and 6M after ECP. 
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Figure 5.2 
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Figure 5.2.  Changes in numbers of Lin-HLA-DR+CD11c+ mDCs and Lin-
HLA-DR+CD123+ pDCs in GVHD and L-CTCL patients before and after ECP.  
Freshly isolated PBMCs from L-CTCL patients and GVHD patients were stained 
using 4-Color Dendritic Value Bundle kit and analyzed by flow cytometry for Lin-
HLA-DR+CD11c+ mDCs and Lin-HLA-DR+CD123+ pDCs. 
A) Percentages of Lin-HLA-DR+CD11c+ mDCs of PBMCs in L-CTCL 
patients at BL, Day 2, 1M, 3/4 M, 6/7 M, and 9-12M after ECP. 
B) Percentages of Lin-HLA-DR+CD11c+ mDCs of PBMCs in GVHD 
patients at BL, Day 2, 1M, 3/4 M, and 6/7 M after ECP.  
C) Percentages of Lin-HLA-DR+CD123+ pDCs of PBMCs in L-CTCL 
patients at BL, Day 2, 1M, 3/4 M, 6/7 M, and 9-12M after ECP. 
D) Percentages of Lin-HLA-DR+CD123+ pDCs of PBMCs in GVHD 
patients at BL, Day 2, 1M, 3/4 M, and 6/7 M after ECP. The dotted 
lines were linear trend lines of change. *Linear mixed model analysis, 
P value: <0.05. 
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Table 5.3. Changes in numbers, ratios, and the expressions of HLA-DR on 
DC subpopulations in all L-CTCL patients treated for 6 months with ECP. 
 
       *: Wilcoxon analysis: the HLA-DR on pDC at 6/7M was significantly lower than baseline in 
non-responders. 
 
 
 
 
 
 
 
 
 
 
 BL Day 2 1 M 3/4 M 6 /7M p-value 
mDC(%) 0.41 0.46 0.31 0.53 0.70 0.0272 
pDC(%) 0.39 0.48 0.30 0.24 0.34 0.0944 
mDC/pDC 
 
1.39 1.26 1.41 2.29 2.27 0.0313 
pDC/mDC 
 
1.05 1.10 1.12 0.80 0.81 0.4600 
HLA-DR on mDC 
 
1919.62 2185.08 1939.03 2115.20 1887.15 0.0815 
HLA-DR on pDC 
 
1460.78 1403.75 1300.20 1531.65 1348.87 0.0380* 
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Ratios of mDCs and pDCs in GVHD and L-CTCL patients are favorably 
altered after ECP  
Human mDCs and pDCs induce different types of Th responses 
depending on environmental factors [8,137]. Skewing of cytokine profiles towards 
Th2 in L-CTCL and towards Th1 in GVHD are thought to associate partially with 
the distinct defects of mDCs and pDCs[133], [68].   Therefore, we next 
determined whether ratios of mDCs and pDCs were affected by ECP. 
Compared to ND (1.34±1.26; 1.34±1.08), GVHD patients possessed 
higher mDC/pDC ratios (5.66±4.55, p<0.05) and lower pDC/mDC ratios 
(0.46±0.52, p<0.05, Table 5.1).  This mDC predominance is consistent with the 
immunopathogenesis of GVHD as a Th1 mediated process. In contrast, 15 of 18 
(83.3%) L-CTCL patients had normal ratios of mDC/pDC (1.06±0.57) and 14 of 
18 (77.8%) L-CTCL patients had normal ratios of pDC/mDC (0.76±0.27) (Table 
5.2).  Three L-CTCL patients had higher than normal mDC/pDC ratios (#11, #15 
& #17; 3.04±0.58, p<0.05), and 3 patients (#4, #5 & #13) had higher than normal 
pDC/mDC ratios (2.68±0.18, p<0.05).  Patient #17 with a Treg phenotype was the 
only L-CTCL patient manifesting a low pDC/mDC ratio (0.27) and a high 
mDC/pDC ratio (3.71).  Among all L-CTCL patients, responders had relatively 
higher mDC/pDC ratios on average compared to non-responders at baseline, but 
the differences were not significant (1.60±0.90 versus 0.98±0.94, p=0.231,Table 
5.3).  These data suggest mDC predominance in GVHD at baseline, but 
relatively balanced DC ratios in most L-CTCL patients despite low DC numbers. 
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Six GVHD patients with complete samples showed a continuous decrease 
in the mDC/pDC ratios during therapy (BL: 5.66±4.55; Day 2: 4.41±3.56; 1M: 
2.95±3.05; 3/4 M: 2.62±3.06; and 6/7 M: 0.48, Figure 5.3C). Conversely, they 
also had increasing pDC/mDC rations (BL: 0.46±0.52; Day 2: 0.65±0.79; 1M: 
0.59±0.36; 3/4 M: 0.72±0.40; and 6/7 M: 2.08, Figure 5.3D).  This supports the 
use of ECP as an immunosuppressive therapy inducing Th2 immune response to 
dampen Th1 mediated GVHD.   
In contrast, L-CTCL patients’ mDC/pDC ratios increased over the course 
of therapy with decreased ratios of pDC/mDC, regardless of clinical responses 
(Figure 5.3A &B).  These trends continued up to 9~12 months after the initial 
ECP treatment in 4 patients who remained on therapy.  In L-CTCL patients with 
normal baseline mDC/pDC ratios, the ratio continued to increase in 11 of 15 
(73.3%) while the ratio of pDC/mDC decreased.  In 2 of 3 patients with high 
mDC/pDC ratios at baseline, the mDC/pDC ratios decreased over therapy and in 
3 of 3 patients with high pDC/mDC ratios at baseline, their ratios decreased after 
ECP (3/3, 100%). Overall, over the course of ECP therapy the average 
mDC/pDC ratio in L-CTCL patients significantly increased from baseline to 3/4 
months and 6/7 months (P value = 0.0313), and the pDC/mDC ratio decreased, 
but not significantly (Table 5.3).  These data suggest that ECP may work 
differently in L-CTCL versus GVHD by favoring mDC predominance in L-CTCL 
while shifting mDC to pDC predominance in GVHD (Figure 5.3E&F).   
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Figure 5.3 
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Figure 5.3.  Changes in the ratios of mDCs and pDCs in GVHD and L-CTCL 
patients before and after ECP.  Freshly isolated PBMCs from L-CTCL patients 
and GVHD patients were stained using 4-Color Dendritic Value Bundle kit and 
analyzed by flow cytometry for Lin-HLA-DR+CD11c+ mDCs and Lin-HLA-
DR+CD123+ pDCs.  
A) The ratio of mDCs versus pDCs (mDC/pDC) in L-CTCL patients at BL, 
Day 2, 1M, 3/4 M, 6/7 M, and 9-12M after ECP.  
B) The ratio of pDCs versus mDCs (pDC/mDC) in L-CTCL patients at BL, 
Day 2, 1M, 3/4 M, 6/7 M, and 9-12M after ECP.  
C) The ratio of mDC/pDC in GVHD patients at BL, Day 2, 1M, 3/4 M, and 
6/7 M after ECP.   
D) The ratio of pDC/mDC in GVHD patients at BL, Day 2, 1M, 3/4 M, and 
6/7 M after ECP. The dotted lines were linear trend lines of changes. *: 
Linear mixed model analysis, P value: <0.05.  
E)  The average of mDC/pDC ratio in L-CTCL (-♦-) versus GVHD (--) at 
BL and after ECP. (F) The average of pDC/mDC ratio in L-CTCL (-♦-) 
versus GVHD (--) at BL and after ECP. 
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Low HLA-DR expression on mDCs and pDCs in GVHD and L-CTCL patients 
is altered after ECP  
As mentioned previously, DCs undergo a maturation process through 
increasing HLA-DR expression  [129].  To determine the maturation status, we 
then evaluated the levels HLA-DR expression by flow cytometry on DCs before 
and after ECP treatment in GVHD and L-CTCL patients’ blood.  
The HLA-DR expression on mDCs was significantly lower in both GVHD 
and L-CTCL patients at baseline (MFI: 2006.65±1157.27 and 1919.62±965.76, 
Table 5.1) than in normal donors (3956.41±1398.29, p<0.01). Sixteen of 18 L-
CTCL patients had lower than normal HLA-DR expression on mDCs 
(1678.11±702.02 MFI, p<0.01, Table 5.2).  HLA-DR levels on pDCs in both 
GVHD and L-CTCL patients were similar to each other and slightly lower 
(1466.11±674.18 and 1495.74±642.70) than normal donors (1860.10±602.57, 
p>0.05).  Half of L-CTCL patients had lower than normal HLA-DR expression in 
pDC at baseline (984.16.11±199.66 MFI, p<0.01).  These data suggest that 
mDCs are immature in most GVHD and L-CTCL patients, and pDCs are 
immature in half of L-CTCL patients before therapy. 
GVHD patients maintained a low expression of HLA-DR on mDCs and 
pDCs after ECP treatment.  In contrast, in L-CTCL patients, HLA-DR expression 
was up-regulated on mDCs after ECP.  Ten of 16 (62.5%) L-CTCL patients with 
low HLA-DR expression on mDCs had higher levels at 6 months after ECP and 8 
of the 10 were responders (80.0%).  However, 3 of 6 non-responders had 
decreased HLA-DR expression on mDCs (3 down, 2 up, 1 no change).  At 6 
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months after ECP, 7 of 9 (77.8%) with low baseline HLA-DR expressions on 
pDCs also were found to have increased levels with 6 of 7 responders (85.7%).  
But, 4 of 6 non-responders had decreased expression of HLA-DR on their pDCs.  
The HLA-DR expression on pDC at 6/7 months in non-responders was 
significantly lower than baseline (P value = 0.0380, Table 5.3). These results 
suggest that ECP not only modulates the DC numbers, but also regulates 
expression of HLA-DR which may reflect their maturity and ability to present 
antigens to T cells. 
HLA-DR and costimulatory/coinhibitory molecules mRNA expressions in L-
CTCL and GVHD are modulated by ECP 
To further assess the maturation status of DCs, we examined mRNA 
expressions of HLA-DR and costimulatory/coinhibitory molecules in PBMCs 
isolated from blood of L-CTCL and GVHD patients.  As indicated in Figure 5A, 
both L-CTCL and GVHD patients’ PBMCs had low mRNA expression of HLA-DR 
at baseline which was consistent with our flow cytometry findings.  Low mRNA 
levels of ICOS and ICOSL were also detected within PBMCs in both diseases but 
were much lower in GVHD patients.  Expression of CD28, CTLA-4, CD80, and 
CD86 mRNA were higher than normal in L-CTCL, but lower than normal in 
GVHD patients.  After 6 months of therapy, increased HLA-DR and decreased 
CTLA-4 mRNA levels were seen in both diseases (Figure 5.4B & C).  Following 
ECP therapy, in GVHD patients, ICOSL levels increased by 17-fold, from -33.6 at 
baseline to -16.3 at 6 month (Figure 5.4B).  Three L-CTCL patients who 
responded to ECP had higher levels of CD86 mRNA (responder: 1.12, versus 
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non-responder: -1.02; rank sum p <0.05) or lower levels of CTLA-4 (responder: 
3.86, versus non-responder: 5.67, rank sum p <0.05) at baseline (Table 5.4).  
After ECP, responders also had higher levels of HLA-DR, CD80, and CD86 
mRNA compared to non-responders (Figure 5.4C & D).  These data suggest 
that ECP may modulate the expression of costimulatory /coinhibitory molecules 
which may affect DC maturation and function in L-CTCL and GVHD patients, 
respectively. 
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Figure 5.4
131  
Figure 5.4. Expression of HLA-DR and costimulatory/coinhibitory molecule 
mRNA in GVHD and L-CTCL patients at baseline and 6 months of ECP.  
Total RNA was extracted from PBMCs, and the first strand cDNA was 
synthesized with RT2 First Strand Kit.  Relative mRNA levels of HLA-DR, CD28, 
CD80, CD86, CTLA-4, ICOS, and ICOSL were assessed with RT2 Profiler 
Human T-cell Activation PCR Array using ABI Prism 700 Sequence Detection 
System.  The fold changes relative to GAPDH were calculated as the levels of 
gene expression, and calibrated with normal donors.   
A) Relative fold changes at BL in L-CTCL versus GVHD patients.  
B)  Relative fold changes at BL versus 6M after ECP in GVHD 
patients. 
C) Relative fold changes at BL versus 6 M after ECP in L-CTCL 
responders (R).  
D) Relative fold changes at baseline versus 6 M after ECP in L-CTCL 
non-responders (NR). *: Rank sum analysis, p<0.05.   
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Table 5.4.  Comparison of baseline parameters in L-CTCL responders and 
non-responders 
 
 
*: Patient#8 is not included 
**: relative fold change compared to normal donor. Data from 3 responders and 3 non-responders 
 
 
 
 
 
 
 
 
Parameters Responders (n=12) Non-responders (n=6) P value 
Age 66.5 (58.0 – 79.0) 71.0(54.0 – 78.0) 0.332 
ECP cycles 9.4 (6.0 -15.0)* 9.2 (6.0 – 12.0) 0.889 
BSA 61.9 (5.0 – 89.0) 71.1 (37.5 – 100.0) 0.315 
SWAT 65.2 (5.0 – 100.0) 72.2 (47.0 – 100.0) 0.247 
CD4+CD26- tumor cells (%) 82.3 (64.2 – 94.7) 66.3 (20.6 – 94.5) 0.054 
Flow cytometry analysis    
     mDC (%) 0.43  ± 0.35 0.39 ± 0.29 0.803 
     pDC (%) 0.30 ± 0.23 0.56 ± 0.78 0.305 
     mDC/pDC 1.60 ± 0.90 0.98 ± 0.94 0.231 
     pDC/mDC 0.89 ± 0.68 1.37 ± 0.97 0.386 
     HLA-DR in mDC (MFI) 1722.43 ± 917.42 2314.00 ± 1019.59 0.199 
     HLA-DR in pDC (MFI) 1369.81 ± 621.54 1642.73 ± 593.30 0.231 
QT-PCR array (fold 
change)** 
   
     HLA-DR -1.01 -1.19  > 0.05 
     CD28 11.02 9.68  > 0.05 
     CTLA-4 3.86 5.67  < 0.05 
     CD80 1.43 1.50  > 0.05 
     CD86 1.12 -1.02  < 0.05 
     ICOS -1.54 -1.55  > 0.05 
     ICOSL -6.56 -6.81  > 0.05 
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5.4 Discussion & Conclusions 
The findings of increased mDC numbers, increased mDC/pDC ratios, and 
up-regulation of CD80, CD86, and HLA-DR expression in two thirds of L-CTCL 
patients after ECP treatment suggest that ECP treatment is associated with a 
favorable mDC modulation in patients with L-CTCL.  Upregulation of mDC and 
Th1 cytokines would be expected to improve the Th2 profile of the malignant T-
cells.  Another possibility is that reduction of malignant cells by apoptosis which 
would decrease levels of Th2 cytokines could also favorably affect the mDC ratio.    
On the other hand, increased pDC/mDC ratios and up-regulation of ICOSL 
found in three fourths of GVHD patients suggest that ECP treatment in this Th1 
mediated disease is associated with a favorable pDC upregulation in patients 
with GVHD leading to a switch from Th1 to Th2 cytokine profiles.  Two thirds of 
L-CTCL patients and all GVHD patients had some degree of reduced levels of  
mDC and pDC numbers at baseline that resulted in imbalanced ratios of mDCs 
and pDCs. Costimulatory/coinhibitory molecules expressed in L-CTCL and 
GVHD in opposite directions are favorably regulated after ECP in this study.  
Although L-CTCL and GVHD have opposite immune-pathogenesis, following 
ECP therapy there are changes of DC numbers, ratios, and expression of 
costimulatory/coinhibitory molecules in a favorable direction in each disease.  We 
conclude that the normalization of DC defects and balancing of DCs towards a 
more normal status by ECP may underlie its efficacy in L-CTCL and GVHD 
patients. 
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The impaired cellular immunity in L-CTCL patients is attributed to several 
factors, one of which is reduced DC populations leading to reduction of IL-12/Th1 
cytokine secretion and a weakened anti-tumor response.  Wyosocka et al. first 
reported the defect in circulating DCs in SS patients,[68] and found that profound 
defects of both mDCs and pDCs were correlated to high tumor burdens. Our 
findings are consistent with their study in that the majority of our L-CTCL patients 
with > 50% circulating CD4+CD26- tumor cells had decreased mDCs and pDCs 
at baseline.  Only one patient (Pt#4) with an intermediate tumor burden had 
normal DC counts.  It was reported that pDCs synergize with mDCs in the 
induction of antigen-specific antitumor immune responses in an experimental 
melanoma mice model [138].  In this study, we found that L-CTCL patients with 
low numbers of pDCs also had low mDC numbers, and patients who had 
relatively normal pDCs tended to have normal mDC counts. Our data suggest 
that a synergistic interaction between mDCs and pDCs may exist in our L-CTCL 
patients.   
After ECP treatment, the numbers of mDCs were increased in most L-
CTCL patients but changes in the numbers of pDCs were less pronounced.  The 
mDC numbers were increased significantly at 3 and 6 months after ECP with the 
highest numbers found at 6 months when clinical responses were most 
pronounced.  The selective increase in mDC numbers after ECP in L-CTCL 
patients is hypothesized to shift DC subpopulations towards a mDC 
predominance.  These results suggest that ECP has a sustained effect on mDCs.   
The source of increased mDCs after ECP treatment is unknown.  They could 
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migrate from the bone marrow, or could have an extended life span, or could 
derive from tissue monocytes. 
The maturation status characterized by the expression of CSSMs on DCs 
is critical for induction of immune responses or immune tolerance [129,130].   
After ECP, apoptotic lymphocytes are phagocytosed by macrophages and DCs, 
and thought to send “danger signals” to the immune system.  A transcriptome 
study of L-CTCL showed that genes associated with DC differentiation, adhesion, 
maturation, and activation(CD40,CD80, and DC-LAMP) were increased in ECP-
treated cells ex vivo [139].  Our study consistently showed that CD80, CD86, and 
HLA-DR expression was up-regulated and CTLA-4 was down-regulated after 
ECP in L-CTCL patients.  Different from their ex vivo study, our study was the 
first to monitor DC kinetic changes in vivo in patients’  circulation while they were 
undergoing ECP over a 6 month period.  Change in mDC numbers along with up-
regulation of HLA-DR and co-stimulatory molecules may enhance mDC 
maturation and activity, and further boost anti-tumor immune responses that are 
thought to be therapeutic for L-CTCL.  This type of immune regulation would be 
expected to exacerbate patients with GVHD. 
Previous studies reported that ECP modulates DC populations in patients 
with GVHD[139-141],[133],[142].   ECP induces a shift from mDCs to pDCs, 
together with a shift from a predominantly Th1 cytokine profile to a Th2 cytokine 
profile in GVHD patients [133].  Consistent with these ex vivo studies, our study 
found that ECP did favorably affect DC subpopulations in GVHD patients in vivo.  
Before ECP treatment, there were low numbers of both mDCs and pDCs in 
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GVHD patients with a severe deficiency in pDC numbers resulting in an mDC 
predominant status.  After ECP treatment, both DC subpopulations were 
increased in most GVHD patients.  Of note, the pDC numbers increased more 
than mDC numbers resulting in an increased pDC/mDC ratio or an mDC to pDC 
shift.  This agrees with one prior study reported a decreased mDC numbers in 
GVHD patients after ECP [133].  Differences between our study and theirs may 
due to our mixed acute and chronic GVHD patient group, in vivo assessment, 
and different combinations of immunosuppressive therapies.  
As mentioned before, IL-3 stimulation of pDCs induces a Th2 response, 
and could also induce T-reg [8].  A recent study reported that monocyte-derived 
DCs in co-culture with ECP-treated PBMCs produce increased quantities of IL-
10, and the co-cultured DCs expressed reduced CD40 and CD86 following 
stimulation with LPS [142].  Our study did not show much change in CD86 
expression, but we did find significant upregulation of ICOSL mRNA expression 
in PBMCs of GVHD patients.  The expression of ICOSL on pDCs is critical for 
inducing IL-10-producing Treg and immune tolerance [8],[143].  Thus, our results 
suggest that ECP could induce a shift from mDCs to pDCs in GVHD patients in 
vivo, and this change along with an increase of ICOSL may enhance pDC 
activity, and further promote a Th2 response and immune tolerance to allo- or 
auto-reactivity.   
The extent of immune stimulation depends not only on the maturation 
state of DCs, but also on the local cytokine milieu. In a pro-inflammatory 
environment, DCs undergo maturation and the effector immune responses are 
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amplified.  In contrast, in the absence of suitable inflammation, immune tolerance 
develops toward the acquired antigen.  Clinical and hematological improvements 
after ECP in SS patients are associated with a shift from Th2 phenotype to an 
increase of IL-12/Th1 phenotype [108].  A shift of the cytokine profile from Th1 to 
Th2 by ECP in GVHD have already been observed [133].  Therefore, we 
hypothesize that in L-CTCL, ECP treatment not only recruits more circulating 
mDCs, but also creates a pro-inflammatory environment for DCs to mature and 
be activated.  In the presence of the costimulatory molecules, CD80 and CD86, 
these DCs are capable of presenting tumor antigens from phagocytosed tumor 
cells in the context of MHC molecules and thus initiating favorable cellular 
immune responses [144].  In contrast, in GVHD, more pDCs are recruited to the 
peripheral blood favoring the expansion of Th2 clones and secretion of IL-4 and 
IL-10.   When DCs present antigens to T cells in the absence of the costimulatory 
molecules, T-cell anergy or tolerance to transplants or auto-tissues may arise 
[130,133,145]. Our working model is that ECP restores impaired immunity in 
these two diseases by multiple effects including elimination of the pathologic T-
cell populations (Th2 clone in L-CTCL and Th1 clone in GVHD), modulation of 
the cytokine milieu, and correction of DC defects (Figure 5.5).   
In this study, we found high variability in DC numbers, ratios, and HLA-DR 
and costimulatory/coinhibitory molecule expression among L-CTCL patients at 
baseline, suggesting a heterogeneous, complex immunopathogenesis.   
In summary, this translational research study suggests that ECP alone or 
ECP with immunomodulatory therapy favorably modulate DC subpopulations in 
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vivo in both L-CTCL and GVHD patients.  This modulation could underlie and 
explain the favorable effects of ECP for both diseases.  Clinical studies 
investigating the effect of IL-12 and DC vaccine in L-CTCL patients depend on 
enhancing DC functions have also been successful [146-148].  Strategies to 
activate DCs are attractive to enhance insufficient immune responses in patients 
with infectious diseases and cancers or can be used as well to attenuate 
excessive immune responses in allergy, autoimmunity and transplantation [149]. 
This study for the first time assesses DC changes in both L-CTCL and GVHD 
patients groups in parallel.  It provides further insight into how ECP could 
effectively treat two immunological diseases with nearly opposite 
immunopathogenesis. 
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Figure 5.5  
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Figure 5.5. The working model of immunologic mechanism of ECP action 
on L-CTCL and GVHD patients.  Along with the shift of cytokine milieu; ECP 
could effectively balance DC subpopulation towards a more normal status in 
patients with L-CTCL and GVHD.  In L-CTCL, ECP treatment not only recruits 
more circulating mDCs, but also creates a pro-inflammatory environment for DCs 
to mature and be activated.  In the presence of the costimulatory molecules, 
CD80 and CD86, these DCs are capable of presenting tumor antigens from 
phagocytosed tumor cells in the context of MHC molecules and thus initiating 
favorable cellular immune responses.  In contrast, in GVHD, more pDCs are 
recruited to the peripheral blood favoring the expansion of Th2 clones and 
secretion of IL-4 and IL-10.   When DCs present antigens to T cells in the 
absence of the costimulatory molecules, T-cell anergy or tolerance to transplants 
or auto-tissues may arise. 
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CHAPTER 6 
SUMMARY & DISCUSSION 
6.1 Summary of Chapter 2:  Efficacies of extracorporeal photopheresis in 
patients with L-CTCL and GVHD in this study.   
In this study, ECP+BRM was clinically effective in L-CTCL and GVHD 
patients as measured by regression of disease in skin or blood.  We confirmed 
the published efficacy of ECP for the treatment of patients with both L-CTCL and 
GVHD.  Our overall response rate was 66.7% in 12 of 18 patients with L-CTCL 
on ECP+BRM and 54.5% in 6 of 11 GVHD patients treated with ECP plus 
immunosuppressive therapies.  Of interest, 4 of 6 (66.7%) L-CTCL patients who 
received ECP alone and 8 of 12 (66.7%) who received ECP with 
immunomodulatory therapy achieved the same overall clinical response rate. 
 
6.2 Summary of Chapter 3:  Effect of extracorporeal photopheresis on 
regulatory T cells in L-CTCL  
In our study, we found in L-CTCL that CD4+CD26- tumor cells correlated 
with percentages of CD4+Foxp3+ and CD4+ Foxp3+CD25- T cells, suggesting that 
tumors cell may have the T-reg phenotype.  At baseline, seven L-CTCL patients 
had high CD4+Foxp3+ T cells (L-CTCL-High, 85.5±20.8%) and 2 patients had low 
CD4+Foxp3+ T cells (L-CTCL-Low, 1.4±1.1%).  Six of the 7 L-CTCL-High patients 
had similar percentages of CD4+Foxp3+ T cells and CD4+CD26- tumor T cells.  
After ECP treatment at 3 months, we found that the percentages of tumor cells 
as well as percentages of Foxp3+ T cells decreased in L-CTCL-High patients.  
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The L-CTCL-Low patients initially had low CD4+Foxp3+ T cells which remained 
low after treatment.  In the GVHD patients, there were 5 patients with high 
CD4+Foxp3+ T-regs (GVHD-High, 90.5±5.7%), 1 Low CD4+Foxp3+ T-regs 
(GVHD-Low, 0.07%), and 1 normal CD4+Foxp3+ T-regs (GVHD-normal, 10.3%).   
In GVHD-High patients, there was a decrease of CD4+Foxp3+ and 
CD4+Foxp3+CD25- T cells by increase in CD4+Foxp3+CD25+ T cells and 4/5 
patients responded.   
This data suggest that ECP may work better in L-CTCL patients with a 
tumor CD4+Foxp3+ T-reg phenotype compared to patients whose tumor cells are 
not of the T-reg phenotype.  In GVHD patients, the high CD4+Foxp3+ T cells may 
be remanent of intial disease.  This suggests that Foxp3 is a possible molecule 
for development of targeted therapies.   
 
6.3 Summary of Chapter 4:  Effect of extracorporeal photopheresis on 
cytotoxic T lymphocytes in L-CTCL and GVHD patients 
Since the numbers and percentages of CD8+ T cells are extremely low in 
L-CTCL patients and cellular cytotoxicity is impaired, CD8+ cytotoxic T 
lymphocytes (CTLs) are hypothesized to also be low and impaired.  As expected, 
we found abnormally low levels of CD8+, CD8+CD69+, and CD8+IFN-γ+ T cells in 
6 available L-CTCL patients prior to treatment.  After treatment, CD8+, 
CD8+CD69+, and CD8+IFN-γ+ T cell numbers increased.  In addition,  CD8+IFN-γ+ 
T cells increased in number after 1 month of treatment in patients whose 
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peripheral blood showed decreases in CD4+CD26- cells tumor cells,  suggesting 
that cellular cytoxicity was improving. 
In GVHD patients, it was expected that CD8+ T cells were high at baseline 
because GVHD is mediated by CD8+ cytotoxic cells.  After treatment, CD8+, 
CD8+CD69+, and CD8+IFN-γ+ T cells decreased.  The decreases in the CD8+ T 
cells show that ECP is favorably down-regulating cellular mediated immunity 
against host targets in GVHD patients.   
 
6.4 Summary of Chapter 5:  Effect of extracorporeal photopheresis on 
dendritic cells in L-CTCL and GVHD patients 
We confirmed the DC defect in L-CTCL and GVHD patients as 
percentages and numbers of mDCs and pDCs were abnormally low prior to 
treatment.  After treatment, the mDCs and pDCs increased suggesting that the 
DC compartment was defective but not completely impaired.  In addition to the 
increase in mDCs and pDCs, HLA-DR, and CSSMs also increased on mDCs and 
pDCs in some L-CTCL and GVHD patients.  The increase of HLA-DR and 
CSSMs suggest that the DCs are maturing and becoming activated.  When ratios 
of mDCs to pDCs were examined after treatment, it was noted that mDCs 
predominated in L-CTCL patients whereas pDCs predominated in GVHD 
patients. These findings suggest that ECP may work differently in L-CTCL and 
GVHD patients.  Depending on the environment, DCs differentiate into subsets 
that elicit appropriate immune responses.  ECP may work by modulating the DC 
compartment towards predominance of mDCs that induce Th1 responses in L-
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CTCL patients and pDCs that induce an immunosuppressive Th2 response in 
GVHD patients, explaining how one treatment may improve both diseases.  
Further in vitro studies to test mDCs and pDCs functions and differentiation in the 
L-CTCL and GVHD setting are needed.      
 
6.5 Overall Discussion 
From this study, we confirmed that ECP is clinically efficacious in L-CTCL 
and GVHD patients.  At the cellular level, mDCs, pDCs, and CTLs were 
modulated in L-CTCL and GVHD patients after ECP+BRM treatment. In L-CTCL 
patients, mDCs and CTLs increased whereas in GVHD patients, pDCs increased 
while CTLs decreased.  These findings support our hypothesis and indicate that 
the mechanism of ECP action is different in L-CTCL and GVHD patients.           
An unexpected finding was that L-CTCL patients fell into two separate groups 
based on CD4+Foxp3+ T cells.  Six of 9 patients had >80% of Foxp3+ T-regs 
which correlated with the percentages of tumor cells while the other 3 patients 
had tumors that did not correlate with T-regs.  All 6 patients with tumor T-regs 
responded whereas the other 3 patients without tumor T-regs did not respond.  
ECP+BRM appears to be more effective in the patients with Foxp3+ malignant 
phenotype cells compared to the patients without the Foxp3+ malignant 
phenotype.   
We are the first to identify these cellular changes in patients in vivo and 
compare between L-CTCL patients versus GVHD patients in relation to clinical 
response.  These data impact not only the clinical aspects of L-CTCL and GVHD, 
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but also translate into a better understanding of L-CTCL and GVHD pathology for 
advancement of the fields.  The increase of mDCs and pDCs in L-CTCL and 
GVHD, respectively, indicate that the differential DC modulation with a positive 
clinical response suggest that these DCs are capable of improving disease 
according to the immune milieu.  The identification of these specific DC subsets 
in these patients shows that the diseased immune system is capable of returning 
to baseline and provides information on what cellular pathway ECP is beneficially 
modulating.  The induction of mDCs and CTLs with a positive clinical response in 
L-CTCL patients suggest that ECP is beneficially working on these cells.  The 
enhancement of these cells can possibly lead to complete responses or 
remission.  Addition of biological modifiers such as cytokines, IFN-γ or IL-12, with 
ECP can target mDCs and/or augment CTLs in L-CTCL patients.  Because we 
observed cellular changes at specific timepoints, addition of biological modifiers 
at timepoints of change may enhance the later response.  For example, we 
observed that CTLs were immediately increased after 24 hours of ECP and 
increased the highest at 1 month then decreased at 3 and 6 months of treatment 
in L-CTCL patients.   The early increase of CTLs may need to be sustained at 
later timepoints to achieve complete responses.  Thus, addition of biological 
modifiers to enhance CTLs at 1 month after initial ECP could be beneficial.   
After the 1 month timepoint, CTLs decreased in L-CTCL patients.  The 
decrease of CTLs may be attributed to T-reg suppression.  Therefore, to 
enhance CTLs, T-regs could be down-regulated with anti-Foxp3 therapy or anti-
PD1 antibody which has been shown to target T-regs and mask the T-reg 
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inhibition of CTLs in melanoma patients [150]. Conversely, in GVHD patients, 
efforts to increase T-regs and decrease CTLs would be beneficial.   Addition of 
anti-CTLA-4 antibody with ECP may expand Foxp3+ T-regs to suppress the 
unwanted CTLs [151].    
Surprisingly, we found a subset of L-CTCL patients with a tumor T-reg 
population.  This finding shifts the paradigm thought that tumors are not T-regs in 
L-CTCL patients.  Tumor T-reg patients were also found to be better responders 
to ECP compared to patients without a tumor T-reg population.   
Since the tumor T-reg patients achieved a better response rate compared to non-
T-reg patients, these findings suggest that ECP is a good treatment modality in 
this subset of patients whereby cells may be more sensitive to ECP.  We are the 
first to identify that tumor T-reg patients are better responders to ECP compared 
to non-tumor T-reg patients. 
The interesting finding that T-regs are tumor cells in a subset of L-CTCL 
patients can help to better diagnose, treat, and improve quality of life.  Since 
Foxp3 is currently a unique identifier for T-regs, it can be used as a biomarker.  
Use of Foxp3 in diagnostic tests should be incorporated with standard tests to 
identify these unique patients to tailor the treatment regime.  By utilizing Foxp3 
during diagnosis and tracking response by Foxp3, can improve the outcome of 
these tumor T-reg patients.      
To address the intriguing question of “Is the mechanism of ECP same or 
different in L-CTCL versus GVHD patients, we conclude that the mechanism(s) 
of ECP action is different in GVHD versus L-CTCL patients.  Although ECP 
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modulated the DCs in both disorders, the favorable increases of mDCs in L-
CTCL patients and pDCs in GVHD patients suggest that these DC subsets may 
be orchestrating opposite T cell responses which is dependent on the disease 
milieu.  
In GVHD patients, the mechanism of ECP action may be through 
immunoregulation by regression of cytotoxic CD8+ T cells and balancing of 
immunity.  The increase of pDCs after ECP treatment in our study patients 
suggest that the pDCs may be orchestrating an opposite T cell response or Th2 
response to balance out the pathogenic Th1 immunity.  The decrease of 
cytotoxic CD8+ T cells in the GVHD patients supports this mechanism and 
increases of T-regs which suppress CD8+ T cells may be occurring.       
In contrast, in L-CTCL patients, the mechanism of ECP may be through 
immunostimulation by improved anti-tumor cyotoxicity.  The vaccination theory of 
ECP action proposed that ECP induces maturation of monocyte-derived DCs that 
injest ECP treated tumor cells, present tumor antigen to CD8+ T cells, and 
induces cytotoxic T lymphocytes to attack tumor cells.  While this mechanism 
may be occurring in these L-CTCL patients undergoing ECP treatment, we found 
that the CD8+ lymphocyte numbers and percentages remained low despite the 
increase after ECP.  However, the lack of dramatic increase in CD8+ T cell 
numbers does not rule out a role for CD8+ T cells in function or cytotoxicity 
against tumor cells after ECP treatment.  Further studies are necessary. 
Because we found a unique subset of L-CTCL patients with malignant T-
regs and they responded better to ECP+BRM compared to the patient cohort 
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without tumor T-regs, we hypothesized that the mechanism of action through the 
regression of malignant T-regs could be not only through the vaccination 
mechanism, but also T-reg plasticity and increased sensitivity of tumor T-regs to 
ECP.  Since T-regs in the normal state have developmental plasticity whereby 
they can change into other Th17 or Th cells in the appropriate setting [152], the 
tumor T-reg decrease may be due to the increase of other Th cell types or the 
tumor T-regs may be changing into other types of cells.  It would be interesting to 
determine the origin of these tumor T-reg cells.  Whether the tumor cells may 
have evolved into T-regs or the T-regs became malignant could be a subject of 
future study for therapeutic potential.   
Another avenue for potential therapy for L-CTCL patients rely on the 
characteristics of these tumor T-regs.  These tumor T-regs may have more 
sensitivity towards ECP treatment which may be due to their unique cellular and 
molecular characteristics.  The tumor T-regs may provide a better anti-tumor 
response because of the increased expression of certain antigens that can 
mediate a strong anti-tumor cyototoxic attack.  The expression of Foxp3 provides 
a biomarker and possible target for therapy in this subset of L-CTCL patients.  
Foxp3 can be used to diagnose patients as well as serve as a marker of clinical 
response to therapies.  Exactly what features make tumor T-regs more sensitive 
to treatment may need to be further investigated. 
Thus, we propose that the mechanism of ECP action in L-CTCL and 
GVHD patients are different and depend on the immune milieu.  Although DCs 
are modulated in both diseases, the T cell responses are different.  The 
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mechanism of ECP action in L-CTCL patients may be through immunostimulation 
by induction of cytotoxic CD8+ T cells whereas the mechanism of ECP action in 
GVHD patients may be through immunosuppression by regression of cytotoxic 
CD8+ T cells and possible induction of T-regs (Figure 6.1).  Future studies are 
needed to monitor T-regs in GVHD patients undergoing treatment, to investigate 
the cytokine milieu before and after ECP, and to discover specific antigens that 
may improve responses to ECP for the ultimate goal of improving the lives of 
patients treated with ECP. 
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Figure 6.1 
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Figure 6.1.  Proposed immunological mechanisms of ECP in L-CTCL and 
GVHD patients.   
A)  ECP can modulate cytokines by shifting the Th1 cytokines dominance 
to Th2 cytokines in clinically responsive GVHD patients [153].   
Improvement of CTCL is associated with shift of Th2 cytokines 
predominance to Th1 cytokines [108].   
B) Dendritic cells are modulated by ECP.  DCs can differentiate from 
monocytes into myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) 
within the plastic treatment apparatus depending on immune milieu.  
The differences in immune milieu in CTCL and GVHD induce mDCs 
and pDCs, respectively.    
C)   MDCs induce an immunostimulatory T cell response through 
induction of CD8+ cytotoxic T lymphocytes for anti-tumor immunity in 
CTCL patients. 
D) PDCs induce an immunosuppressive T cell response through induction 
of CD4+ regulatory T cells for anti-inflammatory reactions to ameliorate 
GVHD, autoimmune disorders, and transplantation rejection.      
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CHAPTER 7 
 
PATIENTS AND METHODS 
 
7.1 Study design and patients.   
Patients with L-CTCL and GVHD starting ECP treatment signed written 
informed consents to enroll in this study between 2007 and 2010.  This study 
was conducted according to the Declaration of Helsinki Principles and the study 
protocol was approved by the University of Texas M D Anderson Cancer Center 
Institutional Review Board.  The ISCL/EORTC revised criteria for MF and SS was 
used for staging and classification.[154]  MF/SS patients were recruited based on 
blood involvement or >50% CD4+CD26- circulating Sézary cells.  All patients 
were starting ECP for the first time and were treated with the UVAR XTS 
photopheresis system (Therakos, Inc. Raritan, NJ).  ECP was administered over 
2 consecutive days every 2 to 4 weeks per cycle for L-CTCL patients and weekly 
for GVHD patients.  Fresh blood was collected before ECP (baseline) and after 
ECP on Day 2 (D2), 1 month (1M), 3 months (3M), and 6 months (6M). Buffy 
coats from normal donors (ND) were obtained from the Department of 
Transfusion Medicine at our institution.  
7.2 Clinical Responses.   
Clinical responses for L-CTCL patients were assessed at 6 months after 
ECP by one expert clinician (MD).  Extent of disease in each body surface area 
(BSA) was calculated and multiplied by 2 for plaques and multiplied by 4 for 
tumors to obtain the modified skin-weighted assessment (mSWAT).[154]  The 
mSWAT was performed for each patient at enrollment and every visit. Peripheral 
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blood CD4+CD26- or CD4+CD7- T-cells were identified as the circulating tumor 
cells by flow cytometry [121,148,155,156]  The clinical responses for L-CTCL 
patients were based on the percentage changes of skin scores and circulating 
tumor cells as described in other clinical trials with modification [154,157-159].  
The changes in SWAT were calculated as [(SWAT score from baseline – SWAT 
score at 6 months)/ SWAT score from baseline × 100].  The tumor cell changes 
were calculated as [(CD4+CD26- circulating T cells from baseline – CD4+CD26- 
circulating T cells at 6 months)/ CD4+CD26- circulating T cells from baseline × 
100] [157-159].  Patients with complete responses (CR) were ones who cleared 
all skin or blood involvement.  Partial responses (PR) were defined as >50% 
improvement in skin or blood involvement.  Minor responses (MR) were defined 
as 25%-50% skin or blood improvement.  Patients with CR, PR and MR were 
grouped as responders. Non-responders included patients with stable disease 
(SD) whose skin or blood changes were within 25% from baseline, and patients 
with progressive disease (PD) who had 25% worsening skin or blood 
involvements from baseline. The clinical responses for GVHD patients were 
assessed by an experienced hematologist (AA), and the detailed response 
criteria for GVHD patients were referred to those used by our institution.[160]  
7.3 Blood Samples.   
Peripheral mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation from whole blood.  Freshly isolated PBMCs were characterized for 
myeloid and plasmacytoid dendritic cells by flow cyotometry.  Slowly 
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cryopreseved PBMCS were analyzed for CD4+Foxp3+ T cell subsets and CD8+ T 
cell subsets by immunofluorescence flow cytometry.   
7.4 Immunofluorescence and intracellular flow cytometry analysis of 
Foxp3+ CD4+ T lymphocyte subsets.    
Thawed PBMCs were incubated with CD3-APC/Cy7 (Biolegend), CD4-
FITC (BDBiosciences), and CD25-PE/Cy7 (Biolegend) immunofluorescence 
antibodies on ice for 30 minutes.  Cells were washed with FACS Buffer (Miltenyi 
Biotech) twice prior to intracellular Foxp3 detection.  A fixation/permeabilization 
buffer from the Foxp3 detection kit (eBioscience) was incubated with PBMC for 
35 minutes at 40 C.  Cells were then washed with a 1X perm/wash buffer 
(eBioscience) prior to incubation with Foxp3-PE antibody (clone PCH101) for 30 
minutes at 40 C.   After incubation, cells were washed twice with 1X perm/wash 
buffer.  Reference counting beads were added to each sample (Spherotech).  
Cells were run on a Gallios flow cytometer (Beckman Coulter) and analyzed on 
Kaluza (Beckman Coulter) software as per manufacturer’s instructions.  
Percentages of CD4+Foxp3+, CD4+CD25-Foxp3+, CD4+CD25+Foxp3+ T cells 
were calculated out of CD4+ T cells.  Absolute numbers were calculated on the 
ratio of cell counts over bead counts multiplied by the ratio of known bead 
numbers and volume.    
7.5 Immunofluorescence and intracellular flow cytometry analysis of CD8+ 
T cell lymphocyte subsets.   
Thawed PBMC were activated with Leukocyte Activation Cocktail, with BD 
GolgiPlug (BDBiosciences) for 3 hours at 37oC.  After activation, the cells were 
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treated with the Live/Dead Fixable Dead Cell stain kit (Invitrogen) for 30 minutes 
at room temperature.  Cells were then incubated with CD3-FITC (BD 
Biosciences), CD8-APC (Biolegend) immunofluorescence antibodies for 30 
minutes on ice.  Cells were washed with FACS Buffer (Miltenyi Biotech) twice 
prior to intracellular CD69 detection.  A BD Cytofix/Cytoperm™ 
Fixation/Permeabilization Solution Kit (BD Bioscience) was used to fix and 
permeabilize PBMC for 20 minutes at 40 C.  Cells were then washed with a 1X 
perm/wash buffer (BD Bioscience) twice prior to incubation with CD69-PerCyPCy 
5.5 (Biolegend) antibody for 30 minutes at 40 C.   After incubation, cells were 
washed twice with 1X perm/wash buffer.  Cells were then washed with a 1X 
perm/wash buffer (BD Bioscience) twice prior to incubation with IFN-γ –PE (R&D 
Systems) antibody for 30 minutes at 40 C. Reference counting beads 
(Spherotech) were added prior to flow cytometry.   Cells were run on a Gallios 
flow cytometer (Beckman Coulter) and analyzed on Kaluza (Beckman Coulter) 
software as per manufacturer’s instructions.  Percentages of CD3+CD8+, 
CD3+CD8+CD69+ and CD3+CD8+ IFN-γ + T cells were calculated out of 
CD3+CD8+ T cells.  Absolute numbers were calculated based the ratio of cell 
counts over bead counts multiplied by the ratio of known bead numbers and 
volume.  Numbers of unactivated cell subsets were compared to activated cell 
subsets.    
7.6 Immunofluorescence flow cytometry analysis of myeloid and 
plasmacyotid dendritic cells.  
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Lin-HLA-DR+CD11c+ mDCs and Lin-HLA-DR+CD123+ pDCs were 
analyzed using 4-Color Dendritic Value Bundle kit (BD Biosciences, San Jose, 
CA) by immunofluorescence flow cytometry.  Freshly isolated PBMCs were 
stained with the following antibodies: Lineage Cocktail 1-FITC (Lin 1) (anti-CD3, 
CD14, CD16, CD19, CD20, and CD56), anti-HLA-DR-PerCP, anti-CD123-PE, 
and anti-CD11c-APC, for 30 minutes on ice.  Cells were washed and fixed before 
subjected to flow cytometry analysis.  Mouse IgG1-PE and IgG2a-APC were 
used as isotype controls.  The Lin-HLA-DR+CD11c+ mDC and Lin-HLA-
DR+CD123+ pDC portions were gated with Becton-Dickinson LSR II (BD 
Biosciences, San Jose, CA), and the acquired data were analyzed in FCS 
Express Version 3 (DeNovo software, Los Angeles, CA).  The percentages, 
ratios, and the mean fluorescence intensity (MFI) of HLA-DR expression of 
mDCs and pDCs were calculated for all samples.   
7.7 Quantitative real-time PCR of Foxp3 mRNA expression.   
Total RNA was extracted from PBMCs with Rneasy Mini kit (Qiagen, 
Valencia, CA).  The first strand cDNA was synthesized from 400ng of total RNA 
with an oligo (dT) 12–18 primer using RT2 First Strand Kit (Qiagen, Valencia, 
CA).  The relative mRNA levels Foxp3 were assessed using ABI Prism 700 
Sequence Detection System (Applied Biosystems Inc. Foster City, CA).  Pre-
formulated TaqMan primer and probe mixes for Foxp3 (Hs00203958) were used 
(Applied Biosystems, Foster City, CA). The fold changes relative to the 
endogenous control gene, glyceraldehyde 3-phosphate dehydrogenase 
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(GAPDH), were calculated as the levels of gene expression, and calibrated with 
normal donors.  
7.8 Quantitative real-time PCR for expression of CSSMs mRNA.  
Total RNA was extracted from PBMCs with RNeasy Mini kit (Qiagen, 
Valencia, CA).  The first strand cDNA was synthesized from 400ng of total RNA 
with an oligo (dT) 12–18 primer using RT2 First Strand Kit (Qiagen, Valencia, 
CA). The relative mRNA levels of HLA-DR, CD28, CD80, CD86, CTLA-4, ICOS, 
and ICOSL were assessed with RT2 Profiler Human T-cell Activation PCR Array 
(SABiosciences, Frederick, MD) using ABI Prism 700 Sequence Detection 
System (Applied Biosystems Inc. Foster City, CA).  SYBR Green-optimized 
primers and pre-formulated PCR master mix were used. The fold changes 
relative to GAPDH were calculated as the levels of gene expression, and 
calibrated with normal donors.  
7.9 Statistical analysis of CD4+ and CD8+ T cell subsets.   
Each parameter was calculated for mean ± standard deviation.  Statistical 
significance of percentages and numbers of CD4+Foxp3+, CD4+CD25+Foxp3+, 
CD4+CD25-Foxp3+, CD3+CD8+, CD8+CD69+, and CD8+IFN-γ+  between L-CTCL 
patients and normal donors, between the 2 L-CTCL patients groups, and 
between baseline and time points after ECP-BRM treatment were determined by 
the student’s T-test and Wilcoxon Rank sum analysis.  P-values less than 0.05 
were considered as significantly different between the experimental groups.  Fold 
changes of greater or less than 2-fold was significantly different in gene 
expression. A correlation was determined by Pearson product-moment 
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correlation coefficient R ≥0.5-1.0 based on the Cohen scale.  Statistical analyses 
were evaluated in Microsoft Office Excel 2007 and PASW Statistics 17.0.  Graph 
Pad Prism and Microsoft Office Excel 2007 were used to design figures.     
7.10 Statistical analysis of Dendritic cell subsets.   
Each parameter (percentage, ratio, and MFI) was summarized using the 
mean (standard deviation) and median (range). The levels at baseline and the 
changes from baseline for each time point were computed.  The linear mixed 
models were used assess the changes (from baseline) as a function of time point 
and clinical response (PR+MR versus PD+SD).  We started with the full model 
with fixed effect of time point, response status, and their interaction, as well as a 
random effect of patients. We sequentially eliminated the interaction and the 
main effect of response in absence of significant effect.  Statistical significance of 
percentages, ratios, and MFI of HLA-DR expression in mDCs and pDCs between 
L-CTCL patients and GVHD patients, between normal donors and patients, and 
between baseline and different time points after ECP were assessed. The 
statistical significance of fold changes of each gene mRNA level between patient 
response groups and before and after ECP was determined by the student’s T-
test and Wilcoxon Rank Sum statistical analysis. Differences between 
experimental groups were considered significant if the p value was less than 
0.05.  Differences in gene expression were also considered meaningful if the fold 
regulations were more or less than 2-fold.  Statistical analyses were conducted 
using SAS 9.2 for Windows (Copyright @ 2011 by SAS Institute Inc., Cary, NC) 
and Microsoft Office Excel 2007. 
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